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ABSTRACT 
Background: Dysglycaemia, defined as type 2 diabetes (T2DM) or impaired glucose 
tolerance (IGT), is a major risk factor for cardiovascular disease (CVD). Dysglycaemia and 
CVD together account for more than half of worldwide mortality. Despite abundant evidence 
stressing the need for early detection and improved cardiovascular prevention in patients with 
dysglycaemia, approximately 50% of people with T2DM are undiagnosed. The early 
identification of dysglycaemia is key to initiating lifestyle changes and pharmacological 
interventions successfully to prevent cardiovascular complications. 
Aims: The general aim of this thesis was to evaluate different screening strategies for 
dysglycaemia with respect to CVD. There were four specific goals: 
1) Compare the prognostic value of fasting plasma glucose (FPG), 2h postload glucose 
(2hPG) and HbA1c in patients with coronary artery disease (CAD) (Study I) 
2) Study the prevalence of dysglycaemia in people treated for hypertension and/or 
dyslipidaemia but without CVD and examine whether using the Finnish Diabetes Risk 
Score (FINDRISC) decreases the need for blood tests in this patient population (Study II) 
3) Examine the effectiveness of different outreach strategies to detect people at high risk of 
T2DM and/or CVD using FINDRISC (Study III) 
4) Study the accuracy of a point-of-care technique used for glucose measurement compared 
with laboratory-based methods (Study IV). 
Methods: Studies I and II were based on data from the EUROASPIRE IV survey, a 
multicentre study of two large cohorts of patients, providing both questionnaire data and 
blood samples: one patient cohort with established CVD and one with hypertension and/or 
dyslipidaemia but without established CVD. In Study III, FINDRISC questionnaire data 
were collected through several outreach channels in the municipality of Södertälje. Response 
rate, risk level and cost effectiveness were compared across channels. In Study IV, glucose 
measurement data from the same patients using different laboratory methods were obtained 
from the EUROASPIRE V survey.  
Results: In Study I, 4,004 patients with CAD but no history of dysglycaemia at baseline 
were followed for a median of 2.03 years. The 2hPG was a significant predictor of future 
cardiovascular events (p=0.01) in contrast to FPG (p=0.45) or HbA1c (p=0.36).  
In Study II, of 2,395 patients with hypertension and/or dyslipidaemia but no history of 
dysglycaemia, 19% had undetected T2DM and 20% IGT. Contrary to the hypothesis, a 
relatively large proportion of patients with low FINDRISC scores had dysglycaemia. 
In Study III, the highest response rate to the FINDRISC was obtained through workplaces. 
The largest proportion of individuals at high risk (≥15/26 points) were outreached through 
the Syrian Orthodox church. The cost of identifying a person at high risk varied greatly 
depending on the choice of outreach strategy. 
Finally, in Study IV, glucose values obtained from the HemoCue® point-of-care system 
correlated well with gold standard hospital laboratory measurements (FPG r=0.94 and 2hPG 
r=0.96; p<0.05) in CAD patients in the EUROASPIRE V survey.  
Conclusions: Future cardiovascular events were only predicted by 2hPG in the present 
cohort of CAD patients. A large proportion of patients with CVD risk factors but without 
established CVD had undetected dysglycaemia. The use of the FINDRISC did not reduce the 
need for blood testing in patients with hypertension and/or dyslipidaemia. The outreach 
strategy affected participation rate, risk level and cost in a large-scale dysglycaemia 
screening. The HemoCue® point-of-care system is accurate for dysglycaemia screening, 
which should save time and costs when performing OGTT.  
SAMMANFATTNING 
Bakgrund: Dysglykemi, definierad som typ 2 diabetes (T2DM) eller nedsatt glukostolerans 
(IGT), är en allvarlig riskfaktor för kardiovaskulär sjukdom (CVD). Tillsammans står dessa 
två tillstånd för drygt hälften av alla dödsfall globalt. Screening för dysglykemi är viktigt för 
att tidigt upptäcka och initiera behandling och därmed förbättra prognosen för denna 
patientgrupp. Trots detta beräknar man att ungefär 50% av alla individer med T2DM är 
oupptäckta.  
Mål: Huvudsyftet med denna avhandling var att undersöka olika screeningstrategier för 
dysglykemi i relation till kardiovaskulär sjukdom via fyra specifika delmål: 
1) Jämföra det prognostiska värdet av fasteblodsocker (FPG), två timmars glukosbelastning 
(2hPG) från ett oralt glukostoleranstest (OGTT) och HbA1c avseende framtida 
kardiovaskulära händelser hos individer med kranskärlssjukdom (studie I). 
2) Undersöka prevalensen av dysglykemi med FPG, 2hPG och HbA1c hos patienter utan 
kranskärlssjukdom under behandling för de kardiovaskulära riskfaktorerna hypertoni 
och/eller dyslipidemi samt undersöka om användning av riskskattningsformuläret 
FINDRISC i ett första screeningsteg skulle kunna minska behovet av blodprover (studie 
II). 
3) Undersöka effektiviteten beroende på val av kommunikationskanal vid storskalig 
screening för dysglykemi (studie III). 
4) Undersöka hur tillförlitlig patientnära teknik är för mätning av blodglukos jämfört med 
ackrediterade metoder vid sjukhuslaboratorier (studie IV). 
Metoder: Studie I och Studie II baserades på den europeiska multicenterstudien 
EUROASPIRE IV, som inkluderar en kohort av patienter med och en utan 
kranskärlssjukdom men den senare med kardiovaskulära riskfaktorer. Dessa patienter 
screenades med blodprover och riskskattningsformulär. I Studie III användes flera 
kommunikationskanaler för att screena för dysglykemi med hjälp av FINDRISC bland 
Södertäljes invånare. Deltagandegraden, risknivån samt kostnadseffektiviteten för de olika 
kanalerna jämfördes. I Studie IV analyserades blodglukos från patienter inkluderade i 
EUROASPIRE V med både HemoCue®, patientnära teknik och standard-metoder på 
ackrediterade laboratorier.  
Resultat: I Studie I gav 2hPG prognostisk information (p=0.01) avseende framtida 
kardiovaskulära händelser hos 3775 patienter med kranskärlssjukdom. FPG (p=0.45) och 
HbA1c (p=0.36) var ej prognostiska indikatorer. I Studie II var prevalensen av okänd T2DM 
19% och IGT 20% hos 2395 patienter med hypertoni och/eller dyslipidemi. Prevalensen av 
tidigare oupptäckt dysglykemi var relativt hög även i de lägre riskkategorierna enligt 
FINDRISC. I Studie III var arbetsplatser den kanal som hade högst deltagandegrad vid 
screening med FINDRISC. Däremot var den syrisk ortodoxa kyrkan den 
kommunikationskanal som hade störst andel högriskindivider (≥15/26 poäng enligt 
FINDRISC). Kostnaden för att identifiera en högriskindivid varierade stort beroende på val 
av kommunikationskanal. I Studie IV hade HemoCue® patientnära teknik god 
överensstämmelse med standardmetoderna på sjukhuslaboratorierna (FPG r=0.94 and 2hPG 
r=0.96; p<0.05).  
Slutsatser: Bland de tre rekommenderade testerna för screening av dysglykemi var 2hPG 
den enda som kunde predikterade risken att insjukna i en ny kardiovaskulär händelse under 
en tvåårsperiod hos patienter med CAD. En hög andel av primärvårdspatienter behandlade 
för hypertoni och/eller dyslipidemi hade tidigare oupptäckt dysglykemi. FINDRISC var inte 
ett tillförlitligt första screeningsteg. Val av kommunikationskanal för storskalig screening 
verkar spela stor roll, både för att få hög deltagandegrad, risknivå och öka 
kostnadseffektiviteten. Den patientnära glukosmätningstekniken, HemoCue®, var tillförlitlig 
för screening av dysglykemi. 
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1 INTRODUCTION 
1.1 DYSGLYCAEMIA 
1.1.1 History 
Reference to polyuria, one of the main symptoms of diabetes, is made as early as 1500 BC 
in the Papyrus of Ebers written by Hesy-Ra (Figure 1).1,2 The Indian physicians, Charaka and 
Sushruta (400-500 AD), recognised diabetes as a syndrome with the hallmark of honey-like 
urine. They also identified “krisha” (asthenic) individuals who developed diabetes earlier in 
life compared with “sthula” (obese) individuals who had a later and slower disease onset.3 
The Greek physician, Aretaeus of Cappadocia, who lived in the first century AD, is credited 
with the first accurate description of the disease likening it to “a remarkable affliction... being 
melting down of the flesh and limbs into urine........The flow is incessant, as if from the 
opening of aqueducts............; It takes a long period to form..........; But the patient is short-
lived.............; For, the melting is rapid, the death speedy........; one cannot stop them either 
from drinking or making water............they are affected by nausea, restlessness and a burning 
thirst, and at not distant term they expire”.4 The term “diabetes”, meaning ‘to go through’ or 
‘siphon’ (dia=through, bêtes=to go), is believed to have been coined by Apollonius of 
Memphis in 250 BC. The term ‘mellitus’ (=from honey) was added by Thomas Willis at 
Oxford in 1674.2 
 
In the past two centuries, research has 
improved our understanding of the 
pathogenesis and treatment of 
diabetes. In 1869, Paul Langerhans 
reported on two cellular systems in the 
pancreas and several years later one of 
them was named the “islets of 
Langerhans”.5 In 1889, Joseph von 
Mering and Oskar Minkowski 
demonstrated that dogs in which the 
pancreas had been removed developed 
diabetes.6 This discovery was 
important for the future experiments 
by a quartet of researchers at the 
University of Toronto, Frederick Banting, Charles Best, JJR Macleod and James Collip, who, 
in 1921, extracted pancreatic gland serum from dogs that could reverse hyperglycaemia.2 
Their discovery of insulin dramatically changed the lives of patients with diabetes. Frederick 
Banting and JJR Macleod were awarded the Nobel Prize in Medicine in 1923. However, 
Frederick Banting shared his prize money with Charles Best, while JJR Macleod shared his 
with James Collip.  
 
In 1939, a study of autopsies of patients with diabetes reported an association between 
diabetes and cardiovascular disease (CVD).8 In the 1940s, CVD was the main cause of death 
in the USA.9 To clarify the cause of CVD, the US Public Health Service embarked upon the 
first large-scale cardiovascular epidemiology study in 1948, the Framingham Heart Study, 
which identified several cardiovascular risk factors, including hyperlipidaemia, hypertension 
and, not least, T2DM.9 The latter condition increases the risk of CVD two to four times and 
together T2DM and CVD account for more than half of the global mortality.10 The 
cardiovascular complications of glucose perturbations already begin to develop in prediabetic 
states such as impaired glucose tolerance (IGT).11,12 This is the reason why IGT and T2DM 
are clustered as dysglycaemia in the present PhD project. 
 
Figure 1. Ebers Papyrus (left) and Hesy-Ra (right)7  
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One problem with dysglycaemia is that it remains undiagnosed for many years. As many as 
50% of people with T2DM were undiagnosed in 2017, according to the International Diabetes 
Federation (IDF).13 The identification and multifactorial management of individuals with 
dysglycaemia is crucial for the prevention of CVD. The overarching aim of this thesis was to 
bridge gaps in knowledge regarding dysglycaemia screening with respect to CVD.  
1.1.2 Definition and classification  
The WHO and the American Diabetes Association (ADA) have defined diabetes as a group 
of metabolic disorder characterised by hyperglycaemia resulting from defects in insulin 
secretion, insulin action, or both.14,15 The development of diabetes involves several 
pathogenic processes, from the autoimmune destruction of the pancreatic beta cells, with 
insulin deficiency as a consequence, to different types of abnormality that result in resistance 
to insulin action. The first unified classification of diabetes, based on insulin dependence, 
were developed by the National Diabetes Data Group in 197916, followed by the WHO in 
1980.17 Diabetes is currently classified as belonging to one of the four main aetiological 
categories described below, as proposed by the ADA in 199715 and the WHO in 1999.14  
 
Type 1 diabetes mellitus (T1DM) accounts for 5-10% of all diabetes and is characterised by 
autoimmune or idiopathic beta cell destruction of the pancreas, leading to absolute insulin 
deficiency. The onset usually occurs early in life, but it can occur at any age; for example, 
latent autoimmune diabetes in adults (LADA) where, despite the presence of islet antibodies, 
the progression of autoimmune beta cell failure is slow.  
 
Type 2 diabetes mellitus (T2DM) accounts for 90-95% of all diabetes. The specific aetiologies 
are not known, but the autoimmune destruction of beta cells does not occur. However, 
deficient insulin secretion, frequently in the setting of insulin resistance in the liver and 
muscle, appears to be the common denominator. To compensate for the insulin resistance, 
the pancreatic beta cells initially increase their insulin production.18 With time, the beta cells 
fail to compensate for the insulin resistance and, as a consequence, the postprandial glucose 
levels and subsequently also the fasting glucose levels become elevated. At the time of 
diagnosis, up to 80% of beta cell function is considered lost.19 The onset of T2DM can be 
very discreet, with minor symptoms, and the condition may remain undiagnosed for several 
years. Older people, people with obesity, lack of physical activity, hypertension and/or 
dyslipidaemia run an increased risk of developing this form of T2DM. Some racial/ethnic 
subgroups also run a higher risk and this is often associated with a strong complex and not 
clearly understood genetic predisposition. T2DM is the focus of this thesis.  
 
Gestational diabetes is diabetes that is diagnosed in the second or third trimester of 
pregnancy, without being related to already existing T1DM or T2DM. It affected an 
estimated one in seven births in the world in 2017.13 A meta-analysis of cohort studies 
following women with gestational diabetes between 1960-2009 reported that they had at least 
a seven-fold increase in the risk of developing T2DM in the future compared with those who 
were normoglycaemic during their pregnancies.20 
 
Other specific types of diabetes account for a relatively small proportion of diabetes. This 
group comprises genetic defects in beta cell function or in insulin action, diseases of the 
exocrine pancreas, diabetes induced by drugs, infections, uncommon forms of immune-
mediated diabetes and diabetes associated with other genetic syndromes.  
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1.1.3 Diagnostic criteria  
The current diagnostic criteria for diabetes (Table 1) were issued by the WHO and the 
ADA.21–23 Today, three diagnostic tests are recommended: fasting plasma glucose (FPG), 
two-hour postload glucose (2hPG) from an oral glucose tolerance test (OGTT) or glycated 
haemoglobin A1c (HbA1c). FPG is the level of blood glucose measured after at least eight 
hours of fasting. It reflects the hepatic glucose output during the night.24 During an OGTT, 
75 g of glucose dissolved in 200 ml water is rapidly ingested. Glucose samples are taken 
before (FPG) and after (2hPG) to determine how quickly it is cleared from the blood. The 
2hPG reflects insulin resistance in peripheral tissues and/or reduced capacity of the pancreatic 
beta cells to produce insulin.25 HbA1c represents the ‘weighted average’ of blood glucose 
during the preceding 120 days corresponding to the lifetime of the erythrocytes. Specifically, 
it measures the proportion of the haemoglobin which has been glycated (“coated with 
sugar”).26  
 
Regardless of method, the diagnostic thresholds are related to a level above which diabetes-
induced retinopathy starts to develop.28 The cut-off points were derived from cross-sectional 
studies including Pima Indians, an Egyptian study and the Third National Health and 
Nutrition Examination Survey examining retinopathy across different glycaemic levels.15  
 
In 1985, the WHO stated that epidemiological studies should be restricted to the use of 2hPG, 
only because the fasting state can rarely be assured and because of the strong correlation 
between FPG and 2hPG.29 Since then, the two-hour 75 g OGTT has been an international 
standard for T2DM diagnosis. In 1997, the ADA expert group proposed that the diagnosis of 
T2DM for epidemiological purposes should be based on FPG alone and did not recommend 
the 2hPG.15 The goal of this recommendation was to standardise and facilitate screening for 
T2DM, since many people with T2DM remained undiagnosed. The ADA acknowledged that 
this approach would probably underestimate the prevalence of T2DM compared with the 
OGTT. To include subjects whose OGTT would have been conclusive for diabetes or IGT, 
the ADA lowered the FPG cutoff value from 7.8 mmol/L to 7 mmol/L. HbA1c, historically 
used for monitoring glycaemic control and to identify patients with a high risk of 
microvascular complications, was added as a diagnostic tool for T2DM in 2010 by the ADA23 
and adopted by the WHO in 2011.22 
 
Prediabetic states, characterised by glucose values ranging between normal levels and the 
cut-off for diabetes, include impaired glucose tolerance (IGT = elevated postprandial blood 
glucose detected by an OGTT), impaired fasting glucose (IFG = elevated fasting glucose) 
and high-risk HbA1c according to the ADA. In 2003, the ADA lowered the cut-off  point for 
IFG to 5.6 mmol/L, as the prediction of T2DM over a five-year period appears to increase in 
data analyses in the Pima Indian, Mauritius, San Antonio and Hoorn studies.30 In the 
Mauritius study, for example, the incidence was about 15% for a FPG of 5.5-5.7mmol/L 
compared with 32% for a FPG of 6.1-6.9 mmol/L.31 Due to the lack of evidence of benefits 
in terms of reducing progression to T2DM and cardiovascular events, the WHO did not adopt 
the lower ADA threshold for IFG.21 Nor has the WHO adopted high-risk HbA1c, as there 
does not appear to be a specific level at which the risk of T2DM clearly begins. 
 
 
 
 
 
 
 
 14 
Table 1. Comparison of the World Health Organisation (WHO) and American Diabetes Association (ADA) 
diagnostic criteria for dysglycaemia. All tests are to be repeated twice, except elevated random plasma glucose 
when symptoms are present.  
 
Dysglycaemic category WHO 200621, 201122  ADA 201832  
Type 2 diabetes mellitus 
  
  HbA1c (DCCT1/IFCC2) ≥6.5% (≥48 mmol/mol) ≥6.5% (≥48 mmol/mol) 
  FPG  ≥7.0 mmol/L (≥126 mg/dL) ≥7.0 mmol/L (≥126 mg/dL) 
  2hPG ≥11.1 mmol/L (≥200 mg/dL) ≥11.1 mmol/L (≥200 mg/dL) 
  Random plasma glucose Symptoms + ≥11.1 mmol/L (≥200 mg/dL) Symptoms + ≥11.1 mmol/L (≥200 
mg/dL) Impaired glucose tolerance 
(IGT) 
  
  FPG  <7.0 mmol/L (<126 mg/dL) <7.0 mmol/L (<126 mg/dL) 
  2hPG  ≥7.8 -11.0 mmol/L (≥140-199 mg/dL) ≥7.8 -11.0 mmol/L (≥140-199 
mg/dL) Impaired fasting glucose 
(IFG) 
  
  PG  6.1-6.9 mmol/L (110-125 mg/dL) 5.6-6.9 mmol/L (100-125 mg/dL) 
  2hPG  <11 mmol/L (<200 mg/dL) <11 mmol/L (<200 mg/dL) 
High-risk HbA1c x 5.7-6.4% (39-47 mmol/mol) 
1Standardised to the Diabetes Control and Complications Trial (DCCT) assay. 
2The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) developed a new 
reference method that measures the concentration of only one molecular species of glycated haemoglobin A1c 
(HbA1c) (mmol/mol).33 FPG= Fasting Plasma Glucose; 2hPG=2 hour Postload Glucose. 
1.1.4 Symptoms and complications of dysglycaemia  
Symptoms indicating diabetes include thirst, polydipsia, polyuria, weight loss, sometimes 
with polyphagia, and blurred vision.22 Children with T1DM typically present with 
polyuria/polydipsia, while approximately one-third present with life-threatening diabetic 
ketoacidosis.34 Regardless of the pathophysiology of diabetes, chronic high blood glucose 
levels are associated with long-term damage, dysfunction and the failure of different organs. 
 
Microvascular complications of diabetes include retino-, nephro- and neuropathy and are 
closely related to glycaemic level.35 The macrovascular complications, comprising coronary 
artery disease (CAD), peripheral vascular disease and ischaemic stroke, may start to develop 
several years before the glucose rises in people with T2DM, as illustrated in Figure 2, and 
the underlying mechanisms are not fully understood. In addition, recent studies suggest that 
heart failure is an important and probably underestimated diabetes-related complication.36 
 
Figure 2. Progress of dysglycaemia and its relationship to macro- and microvascular complications. Adapted 
by permission from Laakso et al.37 
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1.1.5 Epidemiology of dysglycaemia 
Diabetes is currently the seventh most common cause of death in the world.38 The estimated 
care costs for people with diabetes are about 673 billon US dollars a year, corresponding to 
12% of global health expenditure.13 According to the IDF, the global prevalence of T2DM is 
expected to increase from 425 million adults in the 20- to 79-year age groups (8.8% of the 
global population) in 2017 to 629 million people (9.9% of the global population) in 
2045.13 The Global Burden of Diseases, Injuries and Risk Factors study reported that the 
mean FPG increased by 0.07 mmol/L per decade or more between 1980 and 2008.39 The 
more recent Non-Communicable Disease Risk Factor Collaboration, including studies based 
on at least a FPG, 2hPG or HbA1c, reported an increasing global prevalence between 1980-
2014 from an estimated 4.3% to 9.0% in men and 5.0% to 7.9% in women.40 About 28% of 
this increase was estimated to relate to a true rise in the prevalence, 40% due to increased 
longevity in the population and 32% due to interaction between these two factors. T2DM 
prevalence was lowest in north- and south-western Europe, around 5-6%. The western 
countries in general appear to be experiencing a plateau in the incidence of T2DM. At the 
other extreme, T2DM prevalence was higher than 20% in Polynesia and Micronesia and 
around 15% in Melanesia and in the Middle East and North Africa. In these regions, there is 
also an increase in prevalence among younger people and at a lower body mass index (BMI), 
compared with western populations. 
1.1.5.1 Swedish data 
A sedentary lifestyle and the prevalence of obesity are increasing in Sweden.41 Accordingly, 
a rise in the prevalence and incidence of T2DM could be expected, but no such clear trend 
has been observed in a number of studies. In a cross-sectional study from northern Sweden, 
the prevalence of T2DM was 5.8% and 6.5% in men and women respectively, without any 
clear increase between 1990 and 2009.42 In a longitudinal study initiated in 1972 at the 
primary healthcare centre in Laxå, an increase in the prevalence of T2DM was observed 
between 1972-1988, from 2.8% and 2.6% in 1972 to 4.5% and 4.6% in 1988 in women and 
men respectively, but no increase was observed between 1988-2001.43 The incidence rate for 
T2DM was 0.3%, without any increase between 1972-2001. In contrast, another study, based 
on the Swedish national drug prescription registry, reported an increasing prevalence of 
T2DM between 2007-2013 from 5.8% to 6.8% but with a stable incident rate of 0.4% in 
2013.44 The authors estimated that, with a constant incidence and continued improvement in 
relative survival, the prevalence will increase to 10.4% in 2050. Furthermore, the prevalence 
of diabetes among immigrants from the Middle East is approximately two times higher 
compared with Swedish-born subjects.45,46 Because the numbers in this group of immigrants 
have increased considerably in recent years,47 the total prevalence of diabetes in Sweden will 
probably increase. 
 
1.1.6 Risk factors for dysglycaemia 
1.1.6.1 Demographic risk factors 
Age is an important risk factor, as approximately 50% of all patients with T2DM are older 
than 60 years.13  Heredity also appears to be an important factor, but its impact seems to differ 
considerably between different populations and in different environments.48 Ethnicity and 
migration are also reported as independent risk factors.49 A literature review of immigrants 
in the Nordic countries reported an excess risk of T2DM in non-European immigrant groups, 
in some cases 10 times the risk of the indigenous population.50 
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1.1.6.2 Lifestyle-related risk factors 
The American Nurses’ Health Study, following nurses free from T2DM and CVD for 16 
years, reported that those with normal body weight, a healthy diet rich in cereal fibre and 
polyunsaturated fat, regular physical activity, moderate alcohol consumption and no smoking 
had a 90% lower incidence of T2DM than those without these lifestyle traits.51 Obesity was 
the strongest risk factor for the development of T2DM in the Nurses’ Health Study. It is 
estimated that obesity explains more than 80% of all cases. In spite of this, several risk factors 
interact and T2DM is often clustered with other risk factors, including hypertension, 
dyslipidaemia, insulin resistance and abdominal obesity, a combination usually referred to as 
the ‘metabolic syndrome’.52 Importantly, a combination of two or more risk factors multiplies 
the risk of CVD.53  
 
 
1.2 CARDIOVASCULAR RISK 
1.2.1 Cardiovascular disease 
1.2.1.1 Epidemiology of cardiovascular disease 
CVD is currently the most common cause of mortality in the world.38 According to the WHO, 
17.9 million people died from CVD in 2016, accounting for 31% of all global deaths. The 
incidence of CVD is increasing worldwide, especially in low- and middle-income countries 
where an estimated 75% of CVD deaths occur. CVD is responsible for 10% of disability-
adjusted life years (DALYs) lost in low- and middle-income countries and 18% in high-
income countries.54  In Europe, CVD caused 3.9 million deaths in 2017, accounting for 45% 
of all deaths in the region.55 Cardiovascular mortality has declined substantially in high-
income countries over the past two decades, but both the absolute number of CVD deaths 
and morbidity have increased, due to a combination of increased longevity and improved 
survival in manifest CVD.56  
1.2.1.2 Pathophysiology of cardiovascular disease 
Approximately 80% of deaths due to cardiovascular causes, such as acute myocardial 
infarction (AMI) or stroke, are related to atherosclerosis,54  a chronic and systemic condition 
of inflammation and lipid accumulation in the arterial wall.57 The condition is built up over 
decades, as illustrated in Figure 3.58 Atherosclerosis stiffens the vessel wall and eventually 
results in the formation of a plaque. Plaques can produce flow-limiting stenosis that lead to 
tissue ischaemia or, due to fissuring, provoke thrombosis that can impede blood flow locally 
(Figure 3d) or embolise and lodge in distal arteries.57 Other cardiovascular causes of 
morbidity and mortality include cardiomyopathies, cardiac arrhythmias, congenital heart 
disease and rheumatic heart disease.54  
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Figure 3. Stages in the development of atherosclerotic lesions (with permission from Libby P et al58). 
a: Normal artery containing three wall layers; b: The initial steps of atherosclerosis characterised by monocytes 
adhering to the intima and migrating into the vessel wall where they transform to macrophages taking up lipids 
and turning into foam cells; c: lesion progression to an atherosclerotic plaque involving the migration of smooth-
muscle cells from the media to the intima, proliferating resident, intimal smooth-muscle cells stimulating 
extracellular matrix synthesis and the creation of a fibrous cap. Plaque macrophages and smooth-muscle cells 
can die in advancing lesions and extracellular lipids derived from dying cells can accumulate in the central 
region of a plaque, often denoted as the lipid or necrotic core; d: The fracture of the fibrous cap puts blood 
coagulation components in contact with tissue factors, thereby triggering a thrombus formation that extends 
into the vessel lumen, impeding blood flow.  
1.2.1.3 Risk factors for cardiovascular disease 
The increase in global life expectancy during the last century naturally increases exposure to 
CVD.56  In addition, trends such as industrialisation, urbanisation, the IT revolution and the 
use of processed (fast) food have led to a successively increasing unfavourable lifestyle made 
up of unhealthy dietary habits, physical inactivity and tobacco use, i.e. an accumulation of 
risk factors for CVD.59 According to the WHO, the global leading risk factors for 
cardiovascular mortality are raised blood pressure (to which 13% of global deaths are 
attributed), followed by tobacco use (9%), raised blood glucose (6%), physical inactivity 
(6%) and overweight and obesity (5%).60 INTERHEART, a case-control study comparing 
patients with AMI and control subjects, reported that smoking, abnormal blood lipids, 
hypertension, T2DM, abdominal obesity and living in an unfavourable psychosocial situation 
increased the risk of AMI, while the consumption of fruits, vegetables, a modest amount of 
alcohol and regular physical activity decreased it.61 This pattern was seen across the world in 
men and women of all ages. It was estimated that genetic susceptibility to AMI only 
explained one per cent of the population attributable risk when added to these nine 
factors.61 The protective effect of alcohol as reported by the INTERHEART study is 
however, the subject of debate. Recently, the Global Burden of Diseases, Injuries and Risk 
Factors Study found some protective effects of alcohol in connection with ischaemic heart 
disease and T2DM among women. However, when the overall health risks associated with 
alcohol consumption such as the risk of cancer, injuries and communicable disease, were 
considered, the protective effects on ischaemic heart disease and T2DM were offset.62  
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1.2.2 The link between dysglycaemia and cardiovascular disease  
T2DM increases the risk of CVD two to four times and together these two conditions account 
for more than half of global mortality.59 Around 20% of patients with AMI have T2DM. 
Furthermore, in patients with AMI, about two thirds have previously unknown T2DM or 
IGT.63 Patients with a combination of CAD and T2DM have a two times higher mortality 
than those without.64 About 50% of the mortality in patients with T2DM is related to 
macrovascular complications.65 According to the SWEDEHEART (Swedish Web-system for 
Enhancement and Development of Evidence-based care in Heart disease Evaluated 
According to Recommended Therapies) annual report, the prognosis after AMI has improved 
in patients both with and without T2DM, but the one-year mortality is still about 30% higher 
in patients with T2DM.66 Furthermore, the presence of IGT increases the risk of future 
cardiovascular events in patients with AMI to an almost similar extent as newly detected 
T2DM.11,12  
 
The exact causes behind the increased risk of CVD in patients with T2DM are not fully 
understood. It has been suggested that the abnormal metabolic state, such as chronic 
hyperglycaemia, dyslipidaemia and insulin resistance that accompanies T2DM, causes 
arterial dysfunction by promoting inflammatory activation, thrombosis and 
vasoconstriction.67 Hyperglycaemia, dyslipidaemia and insulin resistance inhibit nitric oxide 
(NO; vasodilator) formation and increase the formation of reactive oxygen species (ROS).68 
In addition, hyperinsulinaemia and hyperglycaemia stimulate the production of 
vasoconstrictors, most importantly endothelin-1.69  
 
Dyslipidaemia is present in 60-70% of patients with T2DM. It is characterised by elevated 
triglycerides, low high-density lipoprotein (HDL)-cholesterol and the predominance of small, 
dense low-density lipoprotein (LDL)-cholesterol, often without a particular increase in the 
absolute amount of LDL cholesterol.70 The small, dense LDL particles are reactive and more 
likely to undergo oxidation,37 which increases their uptake by smooth-muscle cells and 
macrophages. This promotes the formation of foam cells in the intima (Figure 3), causing a 
cytokine-mediated increase in inflammation and the inhibition of vasodilatory NO 
production, amplifying the atherosclerotic process in T2DM.71 In addition to dyslipidaemia, 
more than 80% of patients with T2DM develop hypertension. Hypertension and T2DM share 
several common pathways involving inflammation, oxidative stress, insulin resistance and 
obesity.72  
 
Heart failure has often been neglected as a cardiovascular complication of T2DM, but it is 
increasingly recognised as a common and serious complication of T2DM. Hyperglycaemia 
is believed to contribute to the fibrotic remodelling of the myocardium, beyond the risk of 
developing ischaemic heart disease and hypertension.36 
 
1.2.3 The prevention of dysglycaemia and cardiovascular disease 
1.2.3.1 Lifestyle intervention 
Several randomised trials have reported on the importance of lifestyle intervention in patients 
with dysglycaemia. In the US Diabetes Prevention Programme, T2DM incidence in 3,234 
people with IGT was reduced by 58% with intensive lifestyle intervention and by 31% with 
metformin compared with placebo after 2.8 years.73 A 16-lesson curriculum covering diet, 
exercise and behaviour modification was designed to help participants achieve a 7% weight 
reduction. Compared with the placebo group, the incidence of T2DM was reduced by 27% 
in the intervention group and 18% in the metformin group during a mean follow-up of 15 
years.74 In the Finnish Diabetes Prevention Study,75 lifestyle intervention aimed to produce 
a weight reduction of at least 5% through healthy diet and moderate-intensity training 
  19 
sessions of 30 minutes a day or more. At follow-up after about seven years, there was a 43% 
relative risk reduction in the incidence of T2DM in the intervention group compared with the 
control group. The first RCT to show that lifestyle intervention in patients with IGT reduces 
future cardiovascular events was the Da Qing study. In 1986, 577 patients with IGT from 
primary care centres in Da Qing, China, were randomised to either a six-year period of 
lifestyle intervention or serving as a control group receiving standard medical care. After 23 
years, the intervention group had significantly lower rates of all-cause mortality, CVD 
mortality and incidence of T2DM compared with the control group. A difference in CVD 
mortality between the intervention and control group was not seen until 12 years after study 
start.76  
1.2.3.2 Glycaemic control 
Glucose-lowering drugs mainly belong to insulin providers (insulin, sulphonylureas, 
meglitinides), incretins (GLP-1 receptor agonists, DPP-4 inhibitors), insulin sensitisers 
(metformin, peroxisome proliferator-activator receptor (PPAR) agonists) and glucose 
reabsorption inhibitors (SGLT-2 inhibitors).77 According to international guidelines, 
metformin is the first-line treatment, although knowledge of its effect on cardiovascular 
events is limited.78 
 
The goal for glycaemic control according to international guidelines has been to lower 
HbA1c to ≤ 7% (≤53 mmol/L), but this target can vary depending on individual patient 
profiles. This recommendation is based on the results of the Diabetes Control and 
Complications (DCCT) Trial from 1993, the first study to demonstrate that patients with 
T1DM, who reached near-normal levels of HbA1c, had a 35% to 70% reduction in the risk 
of the microvascular complications; neuropathy, nephropathy and retinopathy.79 The 
reduction of these complications with intensive therapy persisted during the long-term 
follow-up of the DCCT cohort, the Epidemiology of Diabetes Interventions and 
Complications (EDIC) study.80 It was also noted that the intensive therapy during the DCCT 
had a major effect on cardiovascular outcomes, with a 58% reduction in fatal and non-fatal 
myocardial infarctions and stroke.81  
 
Several randomised clinical trials have addressed the question of whether intensive treatment 
to normalise HbA1c levels can reduce the risk of CVD in patients with T2DM, but the results 
are inconclusive. The UK Prospective Diabetes Study (UKPDS), comparing strict with less 
strict glycaemic control by means of metformin or insulin-based therapy, showed a reduced 
relative risk of developing microvascular complications in the intensively treated group. 
However, the results showed only an insignificant relative risk reduction of 16% (p=0.052) 
for fatal/non-fatal AMI, with a mean HbA1c level of 7.0% vs. 7.9%, an insignificant 11% 
increase in the risk of stroke19 and a 39% lower AMI risk (p=0.01) in a subgroup of 
overweight patients treated with metformin (mean HbA1c 7.4% vs. 7.9%).82 More recent 
randomised trials, Action to Control Cardiovascular Risk in Diabetes (ACCORD)83, the 
Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation 
(ADVANCE)84 and the Veterans Affairs Diabetes Trial (VADT)85 trials failed to show any 
macrovascular benefits as a result of intensive glycaemic control. In the ADVANCE trial, 
there was evidence of ‘thresholds’, with the implication that there was no significant change 
in the risk of macrovascular events and death below an HbA1c level of 7.0% and below 6.5% 
for microvascular events. The risks increased significantly above these thresholds, with a 
40% higher risk of a microvascular event, a 38% higher risk of a macrovascular event and a 
38% higher risk of death for each 1% increase in HbA1c (all p < 0.0001).  
 
There has been a recent paradigm shift, with the last-generation glucose-lowering agents with 
regards to reducing cardiovascular events in patients with established T2DM and CVD or at 
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high risk of such disease. The SGLT-2 inhibitors empagliflozin, in the Empagliflozin 
Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG 
OUTCOME)86, and canagliflozin, in the Canagliflozin Cardiovascular Assessment Study 
(CANVAS), had a significant beneficial impact on major cardiovascular events (MACE = 
cardiovascular death and non-fatal MI and stroke)87, while dapagliflozin had an significant 
beneficial impact on heart failure hospitalisations and cardiovascular death in the 
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.88 Similar reductions in 
major cardiovascular outcomes were seen with the GLP-1 receptor agonists liraglutide, in the 
Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results 
(LEADER)89, semaglutide, in the Trial to Evaluate Cardiovascular and Other Long-term 
Outcomes with Semaglutide (SUSTAIN-6)90, and albiglutide, in the Albiglutide and 
cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease 
(Harmony Outcomes) trials.91 These positive results were achieved at glycaemic levels 
reached by other glucose-lowering drugs. They must therefore relate to so-called pleiotropic 
effects beyond the glucose-lowering capacity. The exact mechanisms are, however, not 
known and more research is needed in order to understand the results. 
1.2.3.3 Multifactorial management 
The ADA and the European Society of Cardiology (ESC) guidelines for the management of 
dysglycaemia and CVD underline the importance of multifactorial risk factor management 
in people with T2DM in order to reduce morbidity and mortality.77,92 Lifestyle modification, 
including smoking cessation, increased physical activity, weight loss, healthy diet patterns 
and the avoidance of alcohol overconsumption, is the base to which pharmacological 
treatment may be added.  
 
The Steno-2 Study investigated the effects of multifactorial risk-factor control by means of 
behaviour modification and pharmacological therapy in patients with T2DM and 
microalbuminuria.93 Long-lasting reductions in the risks of death and cardiovascular events 
including heart failure94 and severe renal dysfunction95 were observed in the group exposed 
to strict multifactorial risk-factor control as compared with patients randomly assigned to 
conventional care. In a population-based study, 271,174 patients with T2DM from the 
Swedish National Diabetes Register were compared with 1,355,870 age- and gender-
matched controls living in the same areas as the patients during a median follow-up period 
of 5.7 years. Patients with four defined risk factors (HbA1c, LDL cholesterol, blood pressure 
and smoking) within recommended treatment targets had little or no age-adjusted excess risk 
of death, AMI or stroke.96 For each risk factor within target range the excess risk of outcomes 
decreased stepwise. The risk of hospitalisation for heart failure was, however, consistently 
higher among patients with T2DM than among controls. An HbA1c outside the target range 
was the strongest predictor of AMI and smoking was the strongest predictor of death.  
1.2.3.4 Implementation of preventive measures 
Despite the wealth of evidence of the need for the detection and cardiovascular prevention of 
patients with dysglycaemia and the feasibility of CVD prevention at population level, the 
implementation of and adherence to these programmes are still far from satisfactory. The 
ESC, together with other partners, has been issuing guidelines for CVD prevention in clinical 
practice since 1994. These guidelines have been updated at regular intervals, most recently 
in 2016.97 The European Action on Secondary and Primary Prevention by Intervention to 
Reduce Events (EUROASPIRE) surveys I-V have been conducted since 1995 under the 
auspices of the Euro Heart Survey programmes of the ESC, with the objective of studying 
how well the guidelines are adhered to in clinical practice across Europe. The surveys 
demonstrate that large proportions of patients do not achieve the recommended targets for 
CVD prevention.98 In EUROASPIRE IV, examining 6,187 patients with established CAD, 
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46% had no T2DM, 19% had newly diagnosed T2DM and 35% had previously known 
T2DM. The combined use of cardio-protective drugs was 53%, 55% and 60% in these 
groups. The guideline-recommended blood pressure target of < 140/90 mmHg was achieved 
in 68%, 61% and 54% and the corresponding LDL-cholesterol target of < 1.8 mmol/L was 
achieved in 16%, 18% and 28%. Among patients with known T2DM, an HbA1c of < 7.0 % 
was reached in 53%, while 11% had an HbA1c of > 9.0%.99 A considerable proportion of the 
patients therefore failed to reach guideline-recommended treatment targets for glycaemic, 
blood pressure and lipid control.  
 
In 2017, an estimated 50% of people with T2DM were undiagnosed, according to the IDF.7 
The highest proportion of people with undetected T2DM lived in Africa (69%) and the lowest 
in Europe (38%), North America and the Caribbean (38%).13 About 20-30% of patients with 
newly detected T2DM already exhibit signs of macrovascular and/or microvascular 
complications at diagnosis.100 Screening for IGT is encouraged by the fact that T2DM can be 
prevented or delayed in approximately 50% of patients with lifestyle and/or pharmacological 
interventions.73,101,102 Furthermore, there is strong evidence that multifactorial risk-factor 
control reduces the risk of future micro- and macrovascular complications of T2DM. 
 
1.3 SCREENING  
1.3.1 Screening criteria 
The criteria for screening adopted by the WHO originate from a report by Wilson and Jungner 
in 1968.103 These criteria outline a number of conditions that should be fulfilled to make 
screening for a defined condition acceptable (Table 2). Through a literature overview of 
different criteria for screening, Andermann et al. revisited and further modified the “classic 
criteria” in 2008 (Table 2).104 Several other aspects reflect changes in western medicine and 
society, such as the focus on evidence-based health care, the awareness of cost-effectiveness 
and quality assurance but also the importance of informed choice.104 They are referred to as 
the “classic criteria”, based mainly on the capacity of the screening tools to detect the 
condition early and the availability of an acceptable treatment. 
Table 2. The Wilson and Jungner screening criteria modified by Andermann et al.104 
▪ The condition sought should be an important health problem  
▪ There should be an accepted treatment for patients with recognised disease  
▪ Facilities for diagnosis and treatment should be available  
▪ There should be a recognisable latent or early symptomatic stage  
▪ There should be a suitable test or examination  
▪ The test should be acceptable to the population  
▪ The natural history of the condition, including development from latent to declared disease, should be 
adequately understood  
▪ There should be an agreed policy on whom to treat as patients  
▪ The cost of case-finding (including diagnosis and treatment of patients diagnosed) should be 
economically balanced in relation to possible expenditure on medical care as a whole  
▪ Case-finding should be a continuing process and not a “once and for all” project  
 
Synthesis of emerging screening criteria proposed over the past 40 years 
▪ The screening programme should respond to a recognised need 
▪ The objectives of screening should be defined at the outset   
▪ There should be a defined target population 
▪ There should be scientific evidence of screening programme effectiveness 
▪ The programme should integrate education, testing, clinical services and programme management 
▪ There should be quality assurance, with mechanisms to minimise potential risks of screening 
▪ The programme should ensure informed choice, confidentiality and respect for autonomy 
▪ The programme should promote equity and access to screening for the entire target population 
▪ Programme evaluation should be planned from the outset 
▪ The overall benefits of screening should outweigh the harm 
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1.3.2 Population screening versus opportunistic screening 
Whether it is more advantageous for subjects with T2DM to be detected via an organised 
screening programme or be tested for T2DM when presenting to a physician for another 
reason, so-called “opportunistic screening”, in terms of reducing the risk of morbidity and 
mortality, is the subject of debate.105,106 The rationale for screening is the potential to 
intervene earlier in the disease course and thereby achieve improved long-term outcomes. 
 
In a study based on a population register of a general practice in Ely, 1,705 individuals, 40 
to 65 years of age, were followed for 18 years with mortality as the outcome. Patients invited 
for T2DM screening in intervals of five years from 1990 were compared with those in a 
similar population not invited for screening. Although screening resulted in cases being 
identified about 3 years earlier, it did not impact health outcomes.107 In a Swedish study from 
the primary healthcare centre in Laxå, a diabetes register was established in 1972. 
Approximately 85% of the eligible population had been screened in 2001. After a median 
follow-up of 13.6 years, there was no reduction in total mortality or CVD outcomes in 
screening-detected patients with T2DM compared with those diagnosed clinically.108 In 
another Swedish study, the Västerbotten Intervention Programme,109 residents were invited 
for screening with an OGTT at age 30, 40, 50 and 60 years between 1992-2013. Individuals 
with T2DM detected via this kind of screening had a better outcome than those diagnosed 
through opportunistic screening after an average follow-up of 8.7 years.  
 
The first RCT of large scale population screening for T2DM , the Anglo-Danish-Dutch Study 
of Intensive Treatment In People with Screen Detected Diabetes in Primary Care 
(ADDITION-Europe)110, compared the effect of intensive multifactorial treatment or routine 
care in screening-detected people aged 40-69 years. After a mean follow-up of 5.3 years, a 
significant improvement in CVD risk factors was observed in the intensively treated as 
compared with the control group. However, there was only a non-significant decrease of 17% 
in the incidence of CVD mortality and morbidity. Furthermore, follow-up of the ADDITION-
Cambridge111 and the ADDITION-Denmark112, with a median duration of 9.6 and 9.5 years 
respectively, did not reveal any reduced all-cause, CVD- or T2DM-related mortality 
associated with an invitation to screening through the primary care centres.  
 
At the present time, large scale population screening is not recommended, as most studies 
have failed to show that this kind of strategy is effective in improving prognosis regarding 
cardiovascular events. The most recent Swedish National Guidelines113 recommend 
opportunistic screening based on the results of the ADDITION studies, demonstrating that 
population screening did not impact mortality. Opportunistic screening is also advocated by 
the ESC77, ADA32 and IDF.114 It is expected to be implemented at primary healthcare centres, 
disregarding the fact that the effectiveness of this outreach strategy has been questioned105,112, 
as people at high risk of T2DM, such as those with low socio-economic status or certain 
ethnic minorities, may have limited access to health care or are less likely to attend routine 
health checks.115–122 In spite of this, the 2018 ADA guidelines underline that testing should 
be carried out within a healthcare setting, due to a potential need for follow-up and treatment, 
and not through community outreach.32 The essential contents of these guidelines are 
summarised in Table 3. They recommend screening through an informal assessment of risk 
factors or by means of a risk questionnaire to determine whether there is a need for a 
diagnostic test.  
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Table 3. Summary of guidelines for screening of dysglycaemia according to the American Diabetes Association 
(ADA), European Society for Cardiology (ESC) and International Diabetes Federation (IDF).  
BMI= Body Mass Index; T2DM= Type 2 diabetes mellitus; CVD= Cardiovascular Disease; HDL= High 
Density Lipoprotein; HbA1c= Haemoglobin A1c; IGT= Impaired Glucose Tolerance; IFG= Impaired Fasting 
Plasma Glucose; OGTT= Oral Glucose Tolerance Test; 2hPG= 2 hour Postload Glucose;               
FINDRISC= Finnish Diabetes Risk Score 
The ADA 2018 guidelines32 
 
1) Testing should be considered in overweight or obese (BMI ≥25 kg/m2 or (≥23 kg/m2 in Asian Americans)) 
adults who have one or more of the following risk factors 
▪  First-degree relative with T2DM 
▪  High-risk race/ethnicity (e.g. African American, Latino, Native American, Asian American, Pacific 
Islander) 
▪  History of CVD 
▪  Hypertension (≥140/90 mmHg or on therapy for hypertension) 
▪  HDL cholesterol level <35 mg/dL (0.90 mmol/L) and/or a triglyceride level >250 mg/dL (2.8 mmol/L) 
▪  Women with polycystic ovary syndrome 
▪  Physical inactivity 
▪  Other clinical conditions associated with insulin resistance (e.g. severe obesity, acanthosis nigricans) 
 
2) Patients with prediabetes (HbA1c ≥5.7% [39 mmol/mol], IGT or IFG) should be tested yearly 
 
3) Women diagnosed with gestational diabetes should have lifelong testing at least every three years 
 
4) For all other patients, testing should begin at age 45 years 
 
5) If results are normal, testing should be repeated at a minimum of three-year intervals, with 
  consideration of more frequent testing depending on initial results and risk status 
 
6) To test for T2DM, FPG, 2hPG and HbA1c are equally appropriate 
 
The ESC 2013 guidelines77 
 
1) People should be separated into three different populations  
▪ The general population 
▪ People with assumed glucose perturbations (e.g. obese, hypertensive or with T2DM in the family)   
▪ Patients with CVD 
 
2) In the general population and people with assumed abnormalities, the appropriate screening strategy 
   is initiated with a risk questionnaire, e.g. Finnish Diabetes Risk Score (FINDRISC). In individuals with high 
scores, screening continues  with an OGTT or FPG+HbA1c 
 
3) In CVD patients, screening should be initiated with FPG + HbA1c. If these tests are inconclusive, an  
   OGTT should be performed  
 
The IDF 2017 guidelines114 
 
1) Screen people with risk factors for diabetes attending your local health-care facility 
▪ Risk factors for diabetes include age above 40-45 years, obesity, increased waist circumference, 
hypertension and family history of diabetes 
 
2) Use a locally validated screening test, e.g. FINDRISC. If unavailable, use FPG. 
▪ People with a positive screening test should proceed to a diagnostic test. If the result of that test 
is normal, they should be advised on healthy lifestyle changes and the diagnostic test should be 
repeated every year 
▪ People with a negative screening test should have that test repeated at least every three years 
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1.3.3 Screening methods 
1.3.3.1 The Finnish Diabetes Risk Score 
To limit the cost of large-scale screening by means of glucose measurements, a widely used 
strategy is to use a questionnaire as the first screening tool in an attempt to identify people at 
high risk of developing T2DM.123 Several risk scores have been developed, all addressing 
the known risk factors of T2DM. One of them, the Finnish Diabetes Risk Score (FINDRISC; 
Figure 4), has been tested and found to be accurate in identifying individuals at risk of future 
T2DM, not only in Finland124 but in several other countries.123 In addition, it is valuable for 
the detection of IGT, relates to markers of insulin resistance125 and predicts CVD events and 
mortality.126 The FINDRISC includes eight questions/items (age, BMI, waist circumference, 
physical activity, intake of fruit and vegetables, high blood pressure, history of high glucose 
value and family history of T2DM) which, in combination, provide an assessment of the risk 
of developing T2DM during the upcoming ten years.127 Depending on the response to each 
question, a score (0-26) is set and the respondent is allocated to one of five risk categories 
with a sensitivity of 78%, a specificity of 77% and a predictive value of a negative test of 
99%.124 The FINDRISC provides the potential for the early diagnosis of T2DM, as people 
with a high and very high risk can be recommended a laboratory-based evaluation of their 
glycaemic state. 
 
 
Figure 4. The Finnish Diabetes Risk Score (FINDRISC).124  
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1.3.3.2 FPG, 2hPG or HbA1c? 
There is an ongoing debate regarding the diagnostic tests for dysglycaemia. As outlined in 
Table 4, all screening tests have advantages and disadvantages. The debate focuses mainly 
on the lower sensitivity of FPG and HbA1c than an OGTT. The latter test is, however, more 
time consuming and the reproducibility of the 2hPG has been questioned.128,129 Guidelines 
from the ADA endorse all three methods for detecting T2DM as equally appropriate,78 while 
the ESC guidelines recommend that screening should be initiated with FPG and/or HbA1c, 
followed by an OGTT if these tests are negative.77 Furthermore, it is important to screen for 
IGT that is only disclosed by means of an OGTT, since it significantly increases the risk of 
CVD. 11,12 
 
Table 4. Pros and cons of dysglycaemia screening by means of haemoglobin A1c (HbA1c), fasting plasma 
glucose (FPG) and 2 hour postload glucose (2hPG).128,129 
 
T2DM= Type 2 Diabetes Mellitus; IGT= Impaired Glucose Tolerance  
 
In 1998, the Diabetes Epidemiology: Collaborative analysis of Diagnostic criteria in Europe 
(DECODE) study compared the ADA and WHO recommendations for epidemiological 
studies.130 Data were collected from 13 populations and three occupation-based studies from 
eight European countries. All the studies used both a FPG and a 75 g OGTT. Of the 1,517 
people with newly diagnosed T2DM, 40% met the FPG criterion only, 31% met the 2hPG 
criterion only, while 28% met both criteria. The use of only a FPG would have failed to 
HbA1c (glycated haemoglobin reflecting average glucose level during the last six to eight weeks)  
 
+ Captures chronic hyperglycaemia 
+ Fasting not needed  
+ Greater pre-analytical stability than plasma glucose 
 
- Poor marker of important pathophysiological abnormalities featuring T2DM 
- Variability depending on ethnicity, which is poorly understood.  
- Influenced by erythrocyte turnover (e.g. haemoglobinopathies, malaria, anaemia, blood loss) 
- Influenced by hepatic disease, chronic kidney disease and splenomegaly 
- Cost higher than FPG 
- Delays the diagnosis of T2DM in ~60% of incident cases 
- Relationship to future cardiovascular events in need of clarification 
FPG (lowest level of plasma glucose reflecting hepatic glucose production during the night) 
+ Relatively high sensitivity for the diagnosis of T2DM 
+ Simple and inexpensive 
 
- Overnight fasting 
- Influenced by a variety of conditions (e.g. stress, diet, exercise, smoking) 
- Pre-analytical variability (in particular due to glycolysis) 
- Relationship to future cardiovascular events in need of clarification 
 
2hPG (postload glucose after 75 g glucose intake reflecting insulin resistance and/or decreased beta-cell 
function) 
+ The only test that detects IGT 
+ Reflects impairment of beta cell function and/or reflects insulin resistance 
 
- Overnight fasting 
- Influenced by a variety of conditions (e.g. stress, diet, exercise, smoking) 
- Pre-analytical variability (in particular due to glycolysis) 
- Time consuming (somewhat more than two hours) 
- Relationship to future cardiovascular events in need of clarification 
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diagnose ~30% of people with T2DM. The EUROASPIRE IV survey compared the 
diagnostic features of HbA1c, FPG, 2hPG in 4,004 patients with CAD without previously 
known T2DM.131 An OGTT identified the largest number of patients who actually had 
T2DM. HbA1c alone would have left 83% of those with T2DM undetected The overlap in 
case detection between the these three diagnostic tests were small. An important but 
unanswered question is whether this matters and whether there are any differences in 
cardiovascular outcome for people diagnosed on the basis of a 2hPG, a FPG or an HbA1c,.  
 
The 2hPG, FPG and HbA1c seem to be equal predictors of microvascular complications of 
T2DM, with a threshold for a significant increase of risk with increasing glycaemia.35 
However, as of today, studies with all three of these measurements of glucose metabolism 
have not been large enough to compare their relative abilities to predict cardiovascular 
outcome.  
1.3.3.3 Dysglycaemia in the range of diabetes and cardiovascular outcome 
In patients with manifest T2DM, there is a greater risk of CVD with increasing dysglycaemia. 
In a meta-analysis based on 102 prospective studies in the Emerging Risk Factors 
Collaboration, FPG was non-linearly related to vascular risk. Hazard ratios (HR) were about 
50% higher in people with a history of T2DM and with FPG concentrations of ≥ 7 mmol/L 
than in people with a history of T2DM but FPG of < 7 mmol/L.132 In a study from the Swedish 
National Diabetes Register comprising 18,334 individuals with T2DM, of whom one-fifth 
had a history of CVD (the age, gender and other cardiovascular risk factors adjusted), relative 
risk increased for coronary heart disease by 11-13%, stroke by 8-9%, CVD by 10-11% and 
total mortality by 9-10% with higher baseline as well as mean updated HbA1c levels during 
six years of follow-up.133  
1.3.3.4 IFG, high-risk HbA1c, IGT and cardiovascular outcome 
The relationship between FPG and CVD risk in the ranges below the diagnostic threshold for 
T2DM has been the subject of debate. Studies have reported of a linear relationship, threshold 
effects, a J-shaped association or no association.134 A definite threshold which could be used 
to define T2DM based on the risk of CVD has not been shown.21 In the West of Scotland 
Coronary Prevention Study, FPG was measured in 6,447 men with hypercholesterolaemia 
but no history of CVD or T2DM. An elevated FPG level below the threshold for T2DM was 
a significant risk factor for future T2DM but not for CVD over 15 years of follow-up.135 The 
relationship between FPG and cardiovascular events was further investigated in an analysis 
of 102 prospective studies including 698,782 participants by the Emerging Risk Factors 
Collaboration group of investigators.132 The results showed that IFG is only modestly and 
non-linearly associated with the risk of CVD (HR 1.17; 95% CI 1.08-1.26 for FPG 6.1-6.9 
vs. 3.9-5.6 mmol/L). The DECODE study reported a J-shaped relationship between mortality 
and glucose, with the lowest rates for a FPG glucose of 4.5-6.1mmol/L but with the risk 
increasing significantly at only ≥7.0 mmol/L (the threshold for T2DM diagnosis).136 
However, neither FPG nor HbA1c added significant information regarding future 
cardiovascular events when 2hPG was entered into the statistical model. The 2hPG, in the 
range of IGT or T2DM, was a significant and independent predictor of future cardiovascular 
events. 
 
To summarise, different measurements of glucose metabolism may contribute independent 
information and appear to have different predictive values in direct comparisons. 
Epidemiological studies of general populations and small prospective cohort studies suggest 
that dysglycaemia diagnosed on the basis of a 2hPG is associated with a poorer prognosis 
than dysglycaemia diagnosed by means of an elevated FPG or HbA1c for both mortality and 
CVD. It may be that FPG, 2hPG and HbA1c reflect different glycaemic metabolic processes, 
thereby potentially leading to different associations with mortality and CVD, as it appears 
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that limited data are available on the relative value of all three of these tests in predicting the 
prognosis in patients following an acute coronary syndrome (ACS).  
1.3.3.5 Point-of-care technique 
Since the OGTT includes both a FPG and a 2hPG, accurate, user-friendly point-of-care 
glucose-recording techniques would save time, reduce costs and eliminate preanalytical 
errors, while, at the same time, providing immediately available information on the 
glycaemic state. This is useful and convenient for both patients and professionals. Blood 
glucose measurements in the 24 European countries included in EUROASPIRE IV were 
performed using the photometric point-of-care technique, HemoCue® Glucose 201+ System 
(HemoCue®, Ängelholm, Sweden). However, the accuracy of this equipment for the 
screening of dysglycaemia has been questioned,137 since the conversion of whole blood to 
plasma glucose and adjustment for cholesterol levels may affect the result.138 On the other 
hand, the hexokinase method, frequently used as a reference method in laboratory settings, 
has disadvantages that are not shared by HemoCue®. It is relatively large and non-portable, 
requires careful maintenance and interference and technical malfunctions can easily occur.139 
The storage and transportation of the samples and delays in measurement and conversion to 
plasma glucose values are further challenges.140–142 
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2 AIMS 
The general aim of this thesis was to evaluate different screening strategies for dysglycaemia 
with respect to CVD. The four specific goals were to: 
 
1) Compare the prognostic value of FPG, 2hPG and HbA1c in patients with CAD regarding 
future cardiovascular events and incident T2DM (Study I). 
 
 
2) Explore the prevalence of dysglycaemia in patients treated for hypertension and/or 
dyslipidaemia but without CVD by means of HbA1c, FPG and 2hPG and examine whether 
initiating screening with the FINDRISC questionnaire would reduce the need for these 
blood tests (Study II). 
 
3) Examine the effectiveness of different outreach strategies in identifying individuals at risk 
of T2DM and/or CVD in a Swedish municipality with a heterogeneous population 
comprising a large number of immigrants (Study III). 
 
4) Compare the agreement between glucose measurements made by HemoCue® and 
accredited hospital laboratories in patients with CAD and unknown dysglycaemia and 
investigate between-site agreement comparing local hospital laboratories with a central 
hospital laboratory (Study IV). 
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3 MATERIAL AND METHODS 
3.1 PATIENTS 
This thesis used two main sources of patient data. Studies I, II and IV, dealing with 
methodological issues of importance for dysglycaemia screening, were based on the 
European cross-sectional multicentre EUROASPIRE IV and V surveys, providing both 
questionnaire data and blood samples from large numbers of patients with established CAD. 
Study III, assessing the effectiveness of different outreach strategies used when screening 
for T2DM, derived information from questionnaires distributed to the population of the 
Swedish municipality of Södertälje. 
 
3.1.1 Studies I, II and IV – the EUROASPIRE surveys 
3.1.1.1 General aspects 
The ESC, in collaboration with allied societies, has developed and updated guidelines on 
CVD prevention at regular intervals from 1994 through 2016 (Figure 5). The implementation 
of these guidelines in clinical practice was evaluated by means of five cross-sectional 
surveys, the EUROASPIRE surveys. These surveys have been conducted since 1995 through 
the EURObservational Research Programme of the ESC as outlined in Figure 5.  
 
 
Figure 5. Joint European guidelines and EUROpean Action on Secondary and Primary prevention In order to 
Reduce Events (EUROASPIRE) surveys of cardiovascular disease prevention over time. 
 
Consecutive patients (men and women ≥18-<80 years) were retrospectively identified from 
hospital discharge lists if they had been hospitalised for a first or recurrent CAD event six to 
36 months before enrolment in the survey: (i) coronary artery bypass grafting (CABG); (ii) 
percutaneous coronary intervention (PCI); (iii) acute myocardial infarction (AMI) (ICD-10 
121); and (iv) acute myocardial ischaemia (ICD-10 120). 
 
Within each participating country, one or more geographical areas with a defined population 
were selected and all hospitals serving these populations were identified. Eligible patients 
were invited to attend a study visit. The invitation procedure varied between countries, 
according to local privacy rules and the advice of local ethical committees.  
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EUROASPIRE IV and V included a primary care arm investigating individuals free from 
any manifestations of CVD but at increased cardiovascular risk as they had hypertension, 
dyslipidaemia or T2DM. Patients were identified from the records at general practices selected 
in each of the participating countries according to the structure of the local health services. 
The primary care arm recruited men and women aged ≥ 18-< 80 years without atherosclerotic 
disease, who had been prescribed one or more of the following treatments: (i) blood pressure-
lowering and/or (ii) lipid-lowering and/or (iii) glucose-lowering (diet and/or oral drugs and/or 
insulin) since ≥ 6 months to < 3 years prior to the time of the interview. 
 
Centrally trained research staff reviewed patient medical records and interviewed and 
examined the patients by means of standardised methods, entering the retrieved data into an 
electronic central database. Demographic details, smoking status, history of obesity, 
hypertension, dyslipidaemia, glucose metabolism and medication were obtained from 
medical records. Self-reported information on lifestyle, including dietary habits and physical 
activity, other risk factor management and medication, were obtained at interview. On that 
occasion, the following investigations were performed: height, weight, waist circumference, 
blood pressure, blood lipids, FPG and HbA1c in all participants and postload glucose 
(OGTT) in participants without a history of T2DM. The case record forms were translated 
into all the languages of participating countries and the self-reported questionnaires were 
validated versions for each country. 
3.1.1.2 Patients in Study I 
EUROASPIRE IV was conducted at 79 centres in 24 European countries between May 2012 
and April 2013. A total of 16,426 medical records were scrutinised and 7,998 (49%) patients 
with CAD attended the interview. The diagnostic capacity of FPG, 2hPG and HbA1c was 
investigated by Gyberg et al.131 in 4,004 patients without a history of T2DM for whom full 
information was available on all three tests. The patient cohort (n=3,775) in Study I is based 
on a follow-up of the 4,004 patients studied by Gyberg et al.131 
3.1.1.1 Follow-up data in Study I 
All EUROASPIRE IV centres were asked to complete a single-page follow-up questionnaire 
(Figure 6) for all interviewed participants. To be eligible for Study I, the information had to 
cover ≥ 12 months in ≥ 90% of the patients from the respective centres. Cardiovascular death 
was recorded as death from CAD, stroke and other vascular diseases. Non-cardiovascular 
death was recorded as death from cancer or other causes. Deaths without any reported cause 
were classified as “without known cause”. Non-fatal events were recorded as hospitalisation 
for PCI, CABG, AMI, stroke/transient ischaemic attack (TIA) and heart failure. Follow-up 
information was obtained from patient interviews, medical records, external registries or 
databases (mortality registries, municipal records and archives) or, if needed, by contacting 
relatives or a family doctor. Information was requested on vital status and, in the event of 
mortality, date and cause of death. Information was also obtained on T2DM diagnosed since 
the baseline investigation. The information on follow-up was based on self-reported 
information from the patients in 63%, from hospital records in 27%, from external databases 
in 7% and from a patient’s family member or the family doctor in 3%. Of a total of 4,004 
patients without any history of diabetes at the baseline investigation, screening for 
dysglycaemia with an OGTT and HbA1c revealed that 1,161 (29%) of them had previously 
unrecognised T2DM (FPG ≥ 7 mmol/L or 2hPG ≥ 11.1 mmol/L or HbA1c ≥ 6.5%)131 and 
they were excluded from the analysis for incident T2DM at follow-up. During the original 
screening, 1,079 of these patients had T2DM and 2,696 were free from T2DM. Of these 2,697 
patients, information on incident T2DM was available in 2,609 (97%) at follow-up.  
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Figure 6. Follow-up questionnaire of the EUROpean Action on Secondary and Primary prevention In order to 
Reduce Events (EUROASPIRE) IV patients. 
3.1.1.3 Patients in Study II 
In the primary care arm of EUROASPIRE IV, 4,579 patients were identified between January 
2014 and April 2015 from practice records in 14 European regions. A total of 3,212 of these 
patients, free from previously known dysglycaemia, were being treated for hypertension 
and/or dyslipidaemia. Information from the FINDRISC, the OGTT and HbA1c was missing 
in some of them, leaving 2,395 who constituted the population in Study II.  
3.1.1.4 Patients in Study IV 
Study IV comprised 87 patients with CAD subjected to an OGTT at three hospitals under 
the auspices of EUROASPIRE V: Karolinska University Hospital, Solna, Sweden, and Kings 
Mill Hospital and Milton Keynes University Hospital in the UK.  
3.1.1.5 Laboratory measurements and investigations in Studies I, II and IV  
All laboratory analyses, apart from glucose measurements with the HemoCue® equipment, 
were performed at the central core laboratory for the EUROASPIRE surveys (Disease Risk 
Unit, National Institute for Health and Welfare, Helsinki, Finland).  Total and HDL 
cholesterol and triglycerides were analysed in serum and LDL cholesterol was calculated 
according to Friedewald’s formula.143 Venous blood was drawn in a fasting state (≥10 hours) 
into a tube containing clot activator (Venosafe, Terumo Europe, Leuven, Belgium) for lipid 
assays and into a potassium ethylenediaminetetraacetic acid (EDTA) tube for HbA1c assay.  
HbA1c was analysed in whole blood using an immunoturbidimetric method and expressed in 
mmol/mol, according to IFCC, and %, according to DCCT. The OGTT was performed using 
75 grams of anhydrous glucose in 200 ml of water in the morning after ≥ 10 hours of fasting, 
as described by the WHO.21 Blood for FPG was drawn before the glucose intake with a dip 
safe from the EDTA tube in which the HbA1c was collected. Samples for 2hPG were drawn 
from whole venous blood using an EDTA tube. Plasma glucose was analysed locally with a 
photometric point-of-care technique (HemoCue® Glucose 201+ in EUROASPIRE IV and 
HemoCue® Glucose 201RT in EUROASPIRE V; HemoCue®, Ängelholm, Sweden).  
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In Study IV, venous blood sampling in an EDTA tube and a fluoride/citrate plasma tube was 
performed immediately before and one (1hPG) and two hours (2hPG) after the glucose load. 
Glucose analysis with HemoCue® was performed from the EDTA tubes within 10 minutes 
following sampling. Venous blood samples collected in the fluoride/citrate plasma tubes 
were sent to the participating local hospital laboratories directly after the postload glucose 
sampling. They were analysed three to five hours after sampling with their standard methods. 
To study potential between-site variability in plasma glucose analyses, samples of whole blood 
collected in fluoride/citrate tubes were sent frozen to the central laboratory in Helsinki. These 
samples were stored at -70°C pending analysis.  
 
Height (kg) and weight (cm) were recorded in light indoor clothes without shoes (Scales 701 
and Measuring stick model 220; SECA Medical Measuring Systems and Scales, 
Birmingham, UK). Waist circumference was measured using a metal tape applied 
horizontally at the point midway on the mid-axillary line between the lowest rim of the rib 
cage and the tip of the hip bone (superior iliac crest) with the patient standing.144 Blood 
pressure was recorded in a sitting position with an automatic sphygmomanometer (Omron 
M6; OMRON Corporation, Kyoto, Japan). Physical activity was assessed by means of the 
International Physical Activity Questionnaire (IPAQ; IPAQ core group, Karolinska Institutet, 
Stockholm, Sweden). Anxiety and depression scores were estimated using the Hospital 
Anxiety and Depression Scale (HADS) questionnaires. 
 
Smoking status, in addition to self-reported data, was verified by the concentration of breath 
carbon monoxide using a smoker analyser (Bedfont Scientific, Model Micro+).  
The FINDRISC questionnaire127 (as described on page 21, Figure 4) was integrated as part of 
the interview conducted by the research staff in Study II. 
3.1.1.6 Definitions 
Dysglycaemia, according to the ADA and the WHO, was defined as outlined in Table 1.21–23  
Overweight was defined as a BMI of 25.0-29.9 kg/m2 and obesity as a BMI of ≥ 30 kg/ m2. 
Central obesity was defined as a waist circumference of ≥ 88 cm for women and ≥ 102 cm 
for men.144 Blood pressure was defined as elevated if systolic blood pressure (SBP) was ≥ 
140 mmHg and/or diastolic blood pressure (DBP) was ≥ 90 mmHg. Smoking was defined as 
self-reported smoking or exhaled carbon monoxide of >10 ppm (in those who reported that 
they had stopped smoking).146 The physical activity target was defined as vigorous physical 
activity outside work for ≥ 20 minutes at least once/week. The educational level was defined 
as low if only primary school or less had been completed. 
3.1.2 Study III – pilot project in the Municipality of Södertälje  
3.1.2.1 General information 
The Forum for Health Development (Forum för Välfärd; http://www.forumforvalfard.se), 
launched in 2013, is a politically independent platform consisting of representatives with 
knowledge and experience from academia, industry, the health-care sector, government and 
trade unions. One of its initial projects was to show how the prevention of T2DM and/or 
CVD at population level could be approached. For this purpose, an alliance was created with 
researchers at the Cardiology Unit, Department of Medicine at Karolinska Institutet, and it 
resulted in Study III. 
 
Using a community outreach, all the inhabitants of the Municipality of Södertälje aged 18-
65 years (n ~51,000) without known T2DM and/or CVD were encouraged to complete the 
FINDRISC questionnaire during six weeks in May-June 2014. The questionnaire was 
translated into the most common languages in the municipality and was launched as an 
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internet-based survey in Swedish, English, Finnish, Turkish, Assyrian/Syrian and Arabic and 
in a paper version in Swedish and Arabic. 
 
Responders scoring ≥ 15 indicating a high risk of future T2DM and thereby CVD and > 20 
indicating a very high risk of future T2DM and thereby CVD were automatically informed 
about their risk profile and the importance of a healthy lifestyle. In addition, they were 
encouraged to visit a primary healthcare centre for further clinical management or to attend 
a temporary laboratory unit for blood glucose measurements. All the data collected through 
either the paper- or internet-based version of the FINDRISC questionnaire were administered 
at Karolinska Institutet. Blood glucose measurements at the two sites set up for the purpose 
of the study were clinically assessed at Karolinska Institutet, with written information mailed 
to the participant, including advice on further need for care. 
3.1.2.2 Outreach strategies 
Workplaces: an e-mail with information about the survey and a link to the survey was sent 
to the employees at Södertälje County, the Scania Ltd car plant and Södertälje Hospital. For 
the employees at the AstraZeneca Ltd pharma company, information was posted on the 
intranet. It was estimated that 9,883 employees living in Södertälje County were contacted.  
 
Syrian Orthodox churches: at the St Afrem, St Tomas, St Gabriel and St Jacob Syrian 
Orthodox churches, physicians speaking Syrian and Arabic, supported by medical students, 
nursing students and board members of the church, encouraged the church visitors to 
complete the FINDRISC after Sunday worship. The number of questionnaires that were 
distributed were counted by the physicians and amounted to 1,060.  
 
Crowded public places: medical students and nursing students were stationed at public 
places to encourage people to complete the FINDRISC. At football matches, the speaker 
informed the spectators about the survey. The number of people reached could only be 
estimated for the football matches based on the number of tickets sold, which was 7,500.  
 
Primary care centres: the FINDRISC was on display in the waiting room at eight primary 
care centres in Södertälje. The respondents were instructed to return the questionnaires in a 
post box. In addition, at one primary care centre, the FINDRISC was collected either by the 
receptionist or by a doctor or nurse during the appointment. The estimate of the total number 
of people reached was based on a medical data register with information on the weekly 
number of visits per primary care centre and was ~6,300.  
 
Pharmacies: three of the pharmacies in Södertälje were supplied with the questionnaires. If 
requested, a pharmacist helped the customer to complete the survey. According to data on 
the number of visitors provided by the pharmacy managers, the total number people reached 
was ~7,000.  
 
Mass media: articles about the survey were published in the local daily press A Syrian-
speaking physician and a representative from the Forum for Health Development 
participated in a one-hour programme about health on the Syrian TV channel, Syroyo. It 
was not possible to estimate the total number of individuals reached through these channels.  
 
Social media: a Facebook site was created to distribute information about the survey, which 
was also spread on Twitter. Posts regarding the survey were targeted at the inhabitants of 
Södertälje in the 20- to 65-year age group, through Facebook. It was not possible to estimate 
the total number reached by this communication channel.  
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Mail: 10,000 invitational letters with a link to the survey were sent from the “Forum för 
Välfärd” to randomly selected inhabitants. In addition, another 985 letters were sent with 
letterheads representing Södertälje Hospital and 985 letters representing “Forum för Välfärd 
and the Swedish Heart Lung Foundation”, with the incentive of a donation to charity. 
 
3.1.2.3 Cost analysis 
The cost of outreach through a channel was based on the categories of costs as presented in 
Table 5, divided by the number of outreached respondents at high or very high risk. The costs 
of the operational and research team were not included. The cost of processing the channels 
was estimated based on the normal salary of a research nurse. Processing the channels 
included meetings with the collaborating organisations, educating/informing the students and 
physicians at different channels about the study design and their tasks and having meetings 
on the progress of the project.  
 
Table 5. Cost categories for outreach through different communication channels. The costs of the operational 
and research teams are not included. 
 
Developing online questionnaires  
Permits 
- From the police for attending public places 
- Renting public space 
- Records from the Swedish National Register of Addresses 
Material 
-Graphic design 
-Printing questionnaires 
-Printing information brochures  
-Stamps 
-T-shirts 
-Banners 
-Measuring tapes 
-Weighing scales 
Advertisements 
Personnel 
– Students staffing the channels 
– Students for transfer of questionnaire data to Excel sheets 
– Physicians staffing the channels 
– Material transport 
Processing channels 
3.1.2.4 Definitions 
The place of birth was defined as “born in Sweden”, “born in another Nordic country”, “born 
in another European country, excluding Nordic countries” and “born outside Europe”.  
Educational level was defined as primary school (grade 1-9), high school (grade 10-12) and 
post-secondary education (e.g. college or university). The level of employment was 
categorised as full time, part time, self-employed, student, unemployed or on sick leave 
(including both part-time and full-time sick leave). 
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3.2 STATISTICAL ANALYSES 
3.2.1 Studies I and II 
Distributions of the baseline characteristics of patients were summarised using means, 
standard deviations and proportions. Included and excluded patients were compared 
according to Mann-Whitney (continuous variables) and chi-square tests (categorical 
variables). HRs for the primary and secondary outcomes, their 95% confidence intervals and 
statistical significances were estimated using the Cox proportional hazards model. To allow 
regional variation in the form of the underlying hazard function, Cox regression models were 
stratified by country. First, HRs and their statistical significance were adjusted for age and 
gender. To study the independent prognostic role of different dysglycaemia markers, 
variables that are known cardiovascular risk factors (educational level, current smoking, 
BMI, systolic blood pressure, LDL cholesterol, statin use, level of physical activity and 
Hospital Anxiety and Depression Scale score) were regarded as potential confounders and 
hence added to the model as covariates. The adjusted multivariate Cox regression model was 
used to show the impact on the risk of cardiovascular events when the 2hPG increased by 
one unit.  
 
In supplementary analyses of data from Study I, a comparable continuous model was 
provided, also including FPG and HbA1c. FPG was added as a quadratic and cubic effect in 
the Cox model to see whether there was a curvilinear association. Furthermore, all models 
were screened for potential multicollinearity and inflation in standard errors of beta 
coefficients was searched for when gradually creating the multivariate models. In addition, 
pairwise Pearson correlation coefficients between glycaemic parameters were studied.  
 
Study II was supplemented with an analysis including area under the receiver operating 
characteristic curve (AUC) that shows the discriminative power of the FINDRISC, FPG and 
HbA1c combined in seven different ways for the prediction of T2DM. All the statistical 
analyses in Studies I-II were undertaken using SAS statistical software (release 9.3 and 9.4) 
at the Department of Public Health, Ghent University, Belgium.  
3.2.2 Study III 
No statistical analyses were undertaken in Study III due to the nature of this study in which 
descriptive analyses were judged to be sufficient.  
3.2.3 Study IV 
In Study IV, descriptive statistics are presented as the median and interquartile ranges (Q1; 
Q3) and the mean. The correlation between the two methods was calculated according to 
Spearman using Excel. The Bland-Altman method was used to plot the bias (the difference 
between the HemoCue® and hospital laboratory measurements, the HemoCue® and the 
central hospital laboratory and the local hospital laboratories and the central hospital 
laboratory) against the corresponding glucose mean.147 Surveillance error grid analysis was 
performed for HemoCue® compared with local hospital laboratory measurements, according 
to the methodology described by Klonoff et al.,148 using a Microsoft Excel™ VBA macro 
program (Microsoft Corporation, Redmond, WA, USA).149 The surveillance error grid 
displays clinical risks on a continuous colour-coded scale relevant to the clinical practice as 
perceived by T2DM experts. 
 
The International Organisation for Standardisation (ISO) have issued criteria for how 
accurate glucose meters should be for use by people with diabetes. The current ISO 
15197:2013 accuracy criteria require that ≥ 95% of meter results fall within ± 0.83 mmol/L 
or ± 15% of the laboratory reference result at blood glucose concentrations of < 5.6 mmol/L 
and ≥ 5.6 mmol/L respectively.150 A comparison of the surveillance error grid with ISO 
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15197:2013 using computer-simulated data pairs with realistic error distribution has 
suggested that a device with ≤ 3% errors outside the surveillance error grid no-risk “green” 
zone would meet the ISO requirements of ≤ 5% data pairs outside the 0.83 mmol/L 15% 
standard limits, while higher percentages outside the surveillance no-risk zone would indicate 
non-compliance with the standard.149 
 
3.3 ETHICAL CONSIDERATIONS 
All studies comply with the Declaration of Helsinki. The separate protocols were approved 
by the Regional Ethical Review Board in Stockholm. The responsible national co-ordinators 
ascertained that requirements for ethical approval were adhered to in each country 
participating in the EUROASPIRE surveys. Written and oral informed consent was obtained 
prior to enrolment. Participation in all studies was voluntary and anonymous. 
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4 RESULTS 
4.1 THE PROGNOSTIC VALUE OF FPG, HBA1C AND 2HPG (STUDY I) 
4.1.1 Cardiovascular events 
4.1.1.1 Original analyses 
After a median follow-up period of 2.03 years, complete information, including all three 
glycaemic tests, was available in 3,775 (94.3%) of the 4,004 patients investigated at baseline. 
The clinical characteristics of included and excluded (n=229) patients are presented in Table 
6. The excluded patients were slightly younger, smoked more often, were less physically 
active, had higher HADS Anxiety and Depression scores, lower systolic blood pressure, a 
higher LDL-cholesterol and FPG. Their median age was 64.5 years. Only 9.2% of the patients 
were younger than 50 years and 1.2% were younger than 40 years. 
 
Table 6. Baseline characteristics of the patients with complete and incomplete follow-up data respectively. The 
presented data are proportions (% = no/no of observations x 100), unless otherwise stated.  
 
Variable Follow-up data available 
(n=3,775) 
Follow-up data 
incomplete (n=229) 
p = 
Recruiting event 
   
       CABG 11.1 (419/3775) 12.2 (28/229) 0.15 
       PCI 55.2 (2083/3775) 48.9 (112/229) 
       AMI 23.2 (877/3775) 29.3 (67/229) 
Ischaemia 10.5 (396/3775) 9.6 (22/229) 
Age at interview (years; SD)  63.8 (9.69) 60.8 (11.0) <0.0001 
Gender (females) 23.6 (891/3775) 22.3 (51/229) 0.69 
Time since hospital discharge (years) 1.5 (0.69) 1.5 (0.73) 0.52 
Low educational level 16.8 (632/3750) 20.7 (47/227) 0.15 
Current smoking 15.3 (578/3775) 22.3 (51/229) 0.007 
Regular physical activity 45.0 (1563/3471) 29.5 (62/210) <0.0001 
BMI (kg/m²) 28.6 (4.3) 28.2 (4.6) 0.10 
Obesity 33.1 (1249/3771) 29.0 (66/228) 0.22 
Central obesity 54.6 (2041/3737) 56.7 (122/215) 0.57 
Blood pressure (mm Hg) 
   
       Systolic 132.5 (18.8) 128.4 (17.5) 0.002 
       Diastolic 78.3 (10.8) 78.9 (10.8) 0.38 
Cholesterol (mmol/L) 
   
       Total 4.5 (1.09) 4.8 (1.01) 0.15 
       LDL 2.6 (0.91) 2.7 (0.89) 0.04 
Plasma glucose  
   
       Fasting (mmol/L) 6.4 (0.9)* 5.8 (0.46) 0.003 
       2h postload (mmol/L) 7.9 (2.71)* 6.3 (0.97) 0.58 
HbA1c (%) 5.7 (0.42)* 8.1 (2.59) 0.22 
HADS Anxiety score 5.2 (3.81) 6.3 (4.31) 0.0008 
HADS Depression score 4.4 (3.53) 5.0 (3.82) 0.04 
Pharmacological treatment 
   
        Antiplatelet 93.2 (3504/3761) 94.7 (215/227) 0.42 
        Lipid lowering 85.9 (3231/3761) 83.2 (189/227) 0.28 
        Beta-blockers 81.9 (3080/3761) 80.2 (182/227) 0.54 
        ACE inhibitors 58.8 (2212/3761) 54.2 (123/227) 0.19 
        ARB 15.9 (599/3761) 16.3 (37/227) 0.85 
        ACE inhibitors or ARB 74.2 (2790/3761) 69.2 (157/227) 0.10 
 Diuretics 24.5 (920/3761) 26.4 (60/227) 0.52 
*These values differ from those in the published manuscripts since they have been corrected but the correction 
did not influence the main results. CABG= Coronary Artery By-pass Graft; PCI= Percutaneous Coronary 
Intervention; AMI=Acute Myocardial Infarction; BMI=Body Mass Index; LDL=Low Density Lipoprotein; 
HbA1c= Haemoglobin A1c; ACE=Angiotensin Converting Enzyme; ARB=Angiotensin Receptor Blocker 
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The primary, composite cardiovascular endpoint (first of cardiovascular death, myocardial 
infarction, stroke or hospitalisation for heart failure) occurred in 246/3,775 (6.5%) patients. 
The 2hPG indicating IGT or T2DM (i.e. dichotomised as < 7.8 vs. ≥ 7.8 mmol/L) was a 
statistically significant predictor of the primary composite endpoint (the first occurrence of 
one of the following cardiovascular events: cardiovascular death, hospitalisation for AMI, 
stroke/TIA or for heart failure). New onset of DM constituted the secondary endpoint) with 
an adjusted HR of 1.38 (95% CI 1.07-1.78; p=0.01), as presented in Figure 7. Neither FPG 
nor HbA1c predicted the primary outcome. There was no U- or J-shaped relationship between 
FPG and the primary endpoint. Adding FPG as a quadratic (or even cubic) effect in the Cox 
model did not reveal any curvilinear association (p=0.27 for the quadratic term).  
 
 
Figure 7. Prognostic value of fasting plasma glucose (FPG), 2h postload glucose (2hPG) and haemoglobin A1c 
(HbA1c) for the primary, composite endpoint (the first occurrence of one of the following cardiovascular events: 
cardiovascular death, hospitalisation for acute myocardial infarction, stroke/transient ischaemic attack or for 
heart failure) in 3,775 patients with coronary artery disease free of type 2 diabetes mellitus at baseline. Hazard 
ratio (95% confidence interval) and p-value, adjusted for age and sex. 
 
In the adjusted (age, sex, educational level, current smoking, BMI, systolic blood pressure, 
LDL-cholesterol, statin use, level of physical activity and HADS anxiety and depression 
score) multivariate Cox regression model, an increment of 1 mmol/L in 2hPG increased the 
primary event risk by 6% (HR 1.06; 95%CI 1.01-1.13; p=0.03) independently of the level of 
HbA1c and FPG. The corresponding HR for an increase of 1 SD (2.7 mmol/L) in 2hPG was 
1.18 (95%CI 1.01-1.38; p=0.03). 
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4.1.1.2 Supplementary analyses 
In a supplementary analysis, the mean (SD) for FPG at baseline was 6.4 (0.90) mmol/L, 2hPG 
7.9 (2.71) mmol/L and HbA1c 5.7% (0.42). These values have been corrected and differ from 
those in the published manuscript (Study I). This correction did not influence the results.  
 
When FPG and HbA1c were studied in the comparable continuous model, the risk of the 
primary composite endpoint did not increase significantly for an increment of FPG by 1 
mmol/L (HR 1.01; 95%CI 0.85-1.21; p=0.87) or by 1 SD (0.9 mmol/L) (HR 1.01; 95%CI 
0.87-1.19; p=0.87). Likewise, an increment in HbA1c of 1% (HR 0.83; 95%CI 0.57-1.21; 
p=0.33) or of 1 SD (0.42%) (HR 0.92; 95%CI 0.79-1.08; p=0.33) did not increase the risk of 
the primary cardiovascular endpoint. 
 
All models were screened for potential multicollinearity. No inflation in standard errors of 
beta-coefficients was detected when gradually building the multivariate models. The pairwise 
Pearson correlation coefficients (r) were low between the glycaemic parameters: 0.38 
between FPG and 2hPG, 0.39 between FPG and HbA1c and 0.47 between 2hPG and HbA1c.  
4.1.2  Incident T2DM 
At the time of follow-up, information on incident T2DM was available in 2,609 (97%) of the 
participants, who were free from T2DM at baseline. At that time, 78 (3%) of them had 
developed T2DM. As outlined in Figure 8, FPG between 6.1-6.9 mmol/L was not predictive, 
while both HbA1c between 5.7-6.4% and 2hPG between 7.8-11.0 mmol/L were significant 
predictors. 
 
 
Figure 8. The capacity of fasting plasma glucose (FPG), 2h postload glucose (2hPG) and haemoglobin A1c 
(HbA1c) to predict incident type 2 diabetes mellitus in 2,609 patients without this disease at the baseline 
investigation. Odds ratio (95% confidence interval) and P-value adjusted for age and sex. 
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4.2 DYSGLYCAEMIA IN PATIENTS TREATED FOR HYPERTENSION AND/OR 
DYSLIPIDAEMIA (STUDY II) 
The clinical characteristics of included (n=2,395) and excluded (n=817) patients are 
presented in Table 7. Those excluded from the analysis were more often smokers, less 
physically active and had a lower educational level, higher diastolic blood pressure, FPG and 
HbA1c and were more frequently using lipid-lowering and calcium channel blockers. Of the 
2,395 included patients, 85% were using antihypertensive medication and another 153 
patients had blood pressures in the hypertensive range. As a result, 89% of the population 
had hypertension at the time of examination.  
 
Table 7. Pertinent characteristics of included and excluded patients. *Significance of the difference between 
groups, adjusted for age and sex; **N=177; ****N=167; ****N=668.  
Variable Included 
n = 2395 
Excluded 
n = 817 
p-value* 
Age (years; mean ±SD) 58.1 (7.8) 57.9 (11.7) 0.71 
Female gender (%, n) 60.8 (1457/2395) 57.8 (472/817) 0.13 
BMI (kg/m2; mean±SD)  29.4 (5.0) 29.3 (4.7) 0.38 
Obesity (%, n) 40.8 (976/2395) 39.4 (318/808) 0.52 
Central obesity (%, n) 60.7 (1452/2393) 60.6 (477/787) 0.81 
Smoking (%, n)     
        Current  16.0 (382/2395) 19.7 (161/817) 0.03 
        Past  26.2 (628/2395) 
 
24.8 (203/817) 
 
0.27 
 Hypertension (%, n) 
 
49.1 (1175/2392) 
 
52.1 (420/806) 
 
0.19 
 Blood pressure (mm Hg; mean±SD)    
        Systolic 138.6 (17.9) 139.6 (18.3) 0.20 
        Diastolic  
 
82.8 (10.3) 
 
84.5 (10.7) 
 
0.0002 
 Cholesterol (mmol/L; mean±SD)    
        Total  5.63 (1.19) 5.60 (1.18) 0.63 
        HDL  1.31 (0.32) 1.30 (0.34) 0.29 
        LDL  3.58 (1.03) 3.54 (1.01) 0.52 
Triglycerides (mean±SD) 
 
1.66 (1.02) 
 
1.73 (1.19) 
 
0.56 
 Plasma glucose (mmol/L; mean±SD)    
         Fasting  6.24 (0.91) 6.40 (0.83)** 0.02 
        2h postload  7.34 (2.28) 7.62 (2.26)*** 0.13 
  HbA1c (%) 5.67 (0.50) 5.75 (0.67)**** 0.0003 
Pharmacological treatment (%, n) 
Pharmacological treatment 
 
 
 
 
 
         Aspirin/antiplatelets  27.8 (665/2391) 25.0 (204/815) 0.14 
        Lipid-lowering  31.0 (741/2391) 39.1 (318/814) <0.0001 
        Beta-blockers  30.5 (730/2392) 31.5 (256/813) 0.53 
        ACE inhibitors 48.2 (1153/2392) 49.0 (399/814) 0.71 
        AT-II receptor blockers  18.9 (452/2392) 19.8 (161/813) 0.56 
        Calcium channel blockers  22.4 (535/2392) 26.3 (214/814) 0.03 
        Diuretics  29.4 (703/2391) 31.5 (257/815) 0.21 
 Low educational level (%, n) 10.5 (250/2382) 14.7 (120/816) 0.002 
 Low/moderate physical activity (%, n) 55.4 (1295/2337) 61.5 (487/792) 0.001 
BMI=Body Mass Index; HDL=High Density Lipoprotein; LDL=Low Density Lipoprotein; 
HbA1c=Haemoglobin A1c; ACE=Angiotensin Converting Enzyme; AT-II= Angiotensin II  
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4.2.1 Prevalence of dysglycaemia in patients treated for hypertension and/or 
dyslipidaemia 
According to the OGTT, 934 (39%) had previously undetected dysglycaemia (T2DM 19%, 
IGT 20%). The OGTT identified 92% of patients with T2DM, FPG + HbA1c 90%, FPG 
80%, 2hPG 29% and HbA1c 22% (Figure 9). There was little (8%) overlap between all three 
methods. 
 
 
Figure 9. Proportions and their overlap between screening with fasting plasma glucose (FPG) ≥ 7 mmol/L, 2h 
postload glucose (2hPG) ≥ 11.1 mmol/L, haemoglobin A1c (HbA1c) ≥ 6.5%/48 mmol/mol and combinations 
commonly used in clinical practice (FPG + HbA1c and FPG + 2hPG) in the 492 patients with newly detected 
type 2 diabetes mellitus. 
 
 
 
 
4.2.2 Dysglycaemia in relation to the FINDRISC categories 
Of patients who, according to the FINDRISC, had a low, moderate or slightly elevated risk, 
20, 34 and 41% had dysglycaemia (IGT or T2DM) respectively and, of those in the high and 
very high-risk category, 49 and 71% had dysglycaemia (IGT or T2DM) respectively (Figure 
10).  
 
 
 42 
 
Figure 10. Proportion of patients treated with antihypertensive and/or lipid-lowering drugs with newly detected  
dysglycaemia (type 2 diabetes mellitus [T2DM] and impaired glucose tolerance [IGT]) according to the oral 
glucose tolerance test (OGTT) in each of the Finnish Diabetes Risk Score (FINDRISC) categories. The total 
number of patients in each FINDRISC category is indicated below each bar. 
 
4.2.2.1 Supplementary analyses 
In the supplementary analyses of its discriminative value, the FINDRISC was of some value 
in predicting T2DM (AUC 0.672) (Table 8). This was not, however, convincing, beyond 
what was achieved with a FPG (AUC 0.811) or an HbA1c (AUC 0.836) alone. 
 
 
Table 8. Discriminative power of the Finnish Diabetes Risk Score (FINDRISC), fasting plasma glucose (FPG), 
2h postload glucose (2hPG) and haemoglobin A1c (HbA1c) in 2,395 patients.  
Model 
(including age and sex) 
Likelihood ratio χ² statistics 
(degree of freedom) 
Area under the curve 
(AUC; range 0-1, the higher 
the better) 
FINDRISC 51.5 (3) 0.672 
FPG 225.9 (3) 0.811 
HbA1c  186.8 (3) 0.836 
FINDRISC + FPG 235.5 (4) 0.819 
FINDRISC + HbA1c 204.6 (4) 0.835 
HbA1c + FPG 296.2 (4) 0.862 
FINDRISC + HbA1c + FPG 302.5 (5) 0.865 
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4.3 EFFECTIVENESS OF DIFFERENT OUTREACH STRATEGIES (STUDY III) 
The total number of respondents to the FINDRISC questionnaire through the different 
communication channels was 4,412, of whom 372 (7%) had high/very high risk scores. As 
illustrated in Figure 11 A and B, the highest response rate to the FINDRISC was obtained 
through workplaces (27%) and the largest proportion of respondents at high/very high risk 
through the Syrian Orthodox churches (18%). 
 
 
 
 
Figure 11. Proportion of respondents 
A. To the Finnish Diabetes Risk Score (FINDRISC) reached through different communication channels 
B. At high or very high risk of future type 2 diabetes mellitus, according to the FINDRISC questionnaire, 
identified by different communication channels 
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The proportion reached through primary care centres was 4%, of whom 5% were at elevated 
risk. The respondents reached through workplaces were mainly born in Sweden and 53% had 
post-secondary education compared with those reached via the Syrian Orthodox churches, 
who were mainly born outside Europe and had a lower education (Table 9). Crowded public 
places reached a total of 203 respondents, mass media 234 and social media 200 respectively 
(proportions not known).  
 
Table 9. Characteristics of the respondents reached through different communication channels. The presented 
data are n (%), unless otherwise stated. 
 
Respondents 
 
 
n 
Females 
 
 
n (%) 
Mean age Respondent
sborn 
outside 
Europe 
n (%) 
Respondents 
with post-
secondary 
education 
n (%) 
Smokers 
 
 
n (%) 
Respondents in 
full-time 
employment 
n (%) 
Pharmacies 121 85 (70) 44 18 (15) 57 (47) 20 (17) 70 (58) 
Workplaces 2692 1931 (72) 46 291 (11) 1427 (53) 290 (11) 2323 (86) 
Primary care 251 169 (67) 45 51 (20) 103 (41) 44 (18) 162 (65) 
Churches 205 92 (45) 50 178 (87) 65 (32) 37 (18) 90 (44) 
Crowded 
places 
203 105 (52) 44 128 (63) 100 (49) 47 (23) 87 (43) 
Mail 506 310 (61) 45 94 (19) 255 ((50) 48 (9) 295 (58) 
Mass media 234 184 (79) 51 16 (7) 132 (56) 27 (12) 173 (74) 
Social media 200 132 (66) 41 21 (11) 79 (40) 32 (16) 124 (62) 
Total 4412 3008 (68) 46 797 (18) 2218 (50) 545 (12) 3324 (75) 
 
 
The average cost of identifying a person at elevated risk was €70. The cost of identifying a 
person at elevated risk was €104 via the Syrian Orthodox church compared with €8 through 
workplaces and €112 through primary care centres (Figure 12). 
 
 
Figure 12. The estimated cost in euros (€) of identifying an individual at high/very high risk of future type 2 
diabetes mellitus according to the Finnish Diabetes Risk Score (FINDRISC) by communication channel. The 
estimated cost of crowded public places only included football matches. 
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4.4 THE ACCURACY OF POINT-OF-CARE EQUIPMENT IN SCREENING FOR 
DYSGLYCAEMIA (STUDY IV) 
Two hundred and fourteen pairs of plasma glucose values were analysed from 87 patients, of 
which 85 were in the fasting state, 57 at 1hPG and 72 at 2hPG using HemoCue® monitors 
and local hospital laboratories. The median fasting glucose level was 6.2 mmol/L and the 
interquartile ranges Q1 and Q3 were 5.6 and 6.9 with HemoCue® compared with 5.8 mmol/L 
(5.3; 6.4) at the local hospital laboratories. The corresponding values for the median 2hPG 
were 7.0 mmol/L (6.2; 8.5) with HemoCue® and 6.8 (5.7; 8.8) at the local hospital 
laboratories. The two methods correlated (FPG r=0.94 and 2hPG r=0.96; p<0.05). The 
correlations between glucose values obtained at the local hospital laboratories and the central 
laboratory were r=0.93 for FPG and 1.0 for 2hPG respectively. The plot according to the 
Bland-Altman method showed small differences between HemoCue® and the local hospital 
laboratory method (Figure 13).  
 
 
 
Figure 13. Plot according to Bland-Altman expressing the difference between A) the HemoCue® and hospital 
laboratory measurements; B) HemoCue® and the central hospital laboratory; and C) the local hospital 
laboratories and the central hospital laboratory. 
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In the surveillance error grid, 98.6% of the values were in the deep green zone, indicating no 
risk, while the remaining values (1.4%) were within the light green zone, indicating “slight, 
lower risk” for hypo- or hyperglycaemia with Hemocue® when compared with the reference 
method at the local laboratory (Figure 14). 
 
 
 
 
Figure 14. Surveillance error grid analysis for HemoCue® and the local hospital laboratories. The y-axis depicts 
the HemoCue® readings and the x-axis the local laboratory glucose measurements. The colour-coded risk zone 
definition is according to Klonoff et al.148 The degree of risk for hypo- or hyperglycaemia is coded from 0 
(none) to 4 (extreme). 
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5 DISCUSSION 
5.1 SUMMARY OF MAIN FINDINGS 
1) An OGTT has the best diagnostic capacity of different diagnostic tests for dysglycaemia 
in patients with CAD.131 The main finding of the present investigation (Study I) was that the 
2hPG, but not the FPG or HbA1c, was a significant predictor of future cardiovascular events. 
The implication is that the 2hPG obtained by an OGTT captures aspects of dysglycaemia 
(detection rate and prognostic information) of relevance to the development of CAD that is 
underestimated by both the FPG and HbA1c. 
 
2) There is evidence that underlines the need for the early detection of dysglycaemia to 
prevent or postpone its complications. A large group of particular interest in this respect is 
people free from CVD but with known hypertension and/or dyslipidaemia in whom the 
presence of dysglycaemia raises the cardiovascular risk substantially. The present 
investigation (Study II) revealed that a large proportion of these patients, 39%, had 
previously unknown dysglycaemia. The use of a simple questionnaire, the FINDRISC, 
applied to reduce the demand for blood testing turned out to be inadequate in this population. 
 
3) The investigation of the effectiveness of unconventional outreach strategies on the 
commonly advocated opportunistic screening via primary care centres in a population with a 
high proportion of immigrants (Study III) revealed that the highest response rate was 
obtained through workplaces and the largest proportion of individuals at high risk were 
identified through the Syrian Orthodox churches. The cost of identifying a high-risk person 
varied greatly, depending on the outreach strategy. The implication is that the choice of 
outreach strategy affects the participation rate, the risk group that can be targeted and 
screening costs. 
 
4) The accuracy of point-of-care glucose measurements has been questioned as compared 
with accredited hospital laboratories. The HemoCue® point-of-care system did, however, 
correlate well with laboratory measurements and can be considered accurate for 
dysglycaemia screening (Study IV).  
 
5.2 METHODOLOGICAL CONSIDERATIONS 
5.2.1 Strengths 
The materials and methods upon which this project is based have several strengths. The 
EUROASPIRE database used in Studies I, II and IV is unique, combining data retrieved 
from medical records with face-to-face interviews based on internationally validated 
questionnaires and examinations by trained personnel using the same protocol, 
standardised equipment and including central laboratory measurements. All three 
standard methods for glucose measurements, the FPG, 2hPg and HbA1c, were measured.  
 
Loss to follow-up is a particular problem associated with cohort studies. However, only 6% 
of the patients in Study I were lost to follow-up, which must be regarded as a great strength, 
even though the follow-up period was relatively short.  
 
To investigate the effectiveness of different outreach strategies in a heterogeneous 
population, a multichannel screening approach was initiated in Study III. This was based on 
the assumption that large-scale screening for T2DM could be improved by the choice of 
outreach strategy accounting for the characteristics of the targeted population. 
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The glucose values collected in Study IV were not only compared between the point-of-care 
equipment and the local hospital laboratory, but all tests were also validated at a central, core 
laboratory. 
5.2.2 Limitations 
5.2.2.1 Selection bias 
Selection bias may affect the external validity, i.e. the generalisability, of a study to other 
populations. The populations in Studies I-II are all subjected to the influence of what is 
labelled as self-selection because the centres volunteered to participate in the EUROASPIRE 
surveys. These centres may have a particular interest in cardiovascular prevention and may 
not be representative of other centres in the same country or across Europe. If anything, it is 
therefore likely that the standard of care is higher at these centres than that provided to 
patients in everyday clinical practice.  
 
The patient material in Study I consisted predominantly of men, which could affect the 
generalisability of the results to women. The results do, however, originate from a population 
typical of daily clinical practice and are valid from that perspective. 
 
In Study I, the age ranged between 18-80 years (mean=64). The distribution was thus 
skewed, with only 9.2% of the patients younger than 50 years. Younger patients, who develop 
dysglycaemia and CAD, may differ from older subjects. However, excluding patients 
younger than 50 years did not alter the main results.  
 
In Study III, individuals who completed the FINDRISC voluntarily may be more health 
conscious than those who did not attend screening. People who are more health-conscious 
may run a lower risk of developing T2DM. In contrast, some of the participants may have 
been particularly concerned about their risk of T2DM, e.g. due to a family history of the 
disease. These biases should counteract each other, but, as none of them was quantified, the 
net bias remains unknown.  
 
Another selection bias may be introduced in surveys with low participation rates, as there 
may be important differences between participants and those who abstained from 
participation. In EUROASPIRE IV, only 49% of consecutive patients with established CAD 
identified from medical records attended the interview.151 This may reflect low participation 
in epidemiological research in general,152 but it could also be due to restrictions imposed by  
national and European laws on how often and through which channels the patients can be 
contacted. In some countries, patients can only be contacted via mail, while personal contacts 
are prohibited. Nevertheless, the low participation rate introduces a potential bias, as non-
participants are more likely to have unhealthy lifestyles and poorer risk-factor control.152 The 
present findings would then, if anything, underestimate the true prevalence of dysglycaemia 
and its impact on future cardiovascular events. Likewise, the true prevalence of dysglycaemia 
in Study II may also be higher, as patients who were excluded due to missing data had higher 
blood pressure levels and glycaemic variables.  
 
In Study III, Södertälje was chosen as a community that could be used to study immigrant-
dense populations. The results from this city, with approximately 39% immigrants, cannot 
therefore be immediately generalised to other communities. Moreover, and in the absence of 
a formal comparison between pertinent characteristics of the Syrian and the total population 
of Södertälje, the cohort is not representative of the entire municipality. In spite of this, Study 
III contributes a very important message, namely that it is important to consider the 
characteristics of the screened population when choosing the most efficient outreach 
strategies and that a “universal” screening programme may not be effective. 
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5.2.2.2 Information bias 
The majority of incident T2DM were self-reported diabetes in Study I and the FINDRISC 
questionnaire was self-administered in Studies II and III. One concern when it comes to 
self-reported data relates to recall bias, a systematic error that occurs when participants do 
not recall previous events or experiences accurately or omit details for other reasons. Recall 
bias can threaten the internal validity and credibility of a study.153 Validation studies report 
a specificity of > 90% for self-reported T2DM and a sensitivity of 60-70%.154–156 One study 
reported that patients tended to minimise their dysglycaemia, believing that they had 
“borderline T2DM”, although they were classified as having T2DM in their medical 
records.156 In these studies, sensitivities of self-reported data for other cardiovascular risk 
factors were almost similar to that of T2DM. Based on these studies, it can be assumed that 
the self-reported incident T2DM in Study I may represent an underestimation of the true 
prevalence of dysglycaemia. Furthermore, since a large number of patients at baseline in 
Study I had undiagnosed T2DM, reflecting the low screening rate by health-care providers, 
it is likely that many patients remained undetected during the follow-up period. Another 
uncertainty that arises from not reassessing the patients’ glycaemic status at follow-up in 
Study I is that glycaemic status tends to change over time. This may be important, as the 
prognostic value of glycaemic indicators regarding future cardiovascular events may reflect 
patients whose glycaemic status deteriorates, but it may be less critical in those who return 
towards a better glycaemic status. However, Wallander et al. investigated a population of 
patients with ACS using an OGTT at hospital discharge and after three and twelve months. 
The vast majority, 93%, originally classified as having T2DM, still had dysglycaemia 12 
months later.157 Returning towards normal glucose metabolism was very uncommon. 
 
One further limitation in Studies I-II is that, as in almost all similar epidemiological studies, 
dysglycaemia was based on a single glucose recording rather than, as recommended by the 
WHO for a clinical diagnosis, repeated measurements. 
 
5.2.2.3 Dichotomising glucose 
Glucose, a continuous variable, was dichotomised in Study I according to the diagnostic 
criteria issued by the ADA and the WHO. This kind of dichotomisation may be regarded as 
a simplification, losing information on any changes in the effect of the measured variable 
within the different intervals.158 The reason for dichotomising patients into having either 
normal values or dysglycaemia was to mirror clinical practice, where the diagnosis of 
dysglycaemia is based on certain cut-off levels. Dichotomisation may also be a good strategy 
to present data in a way that is easier to interpret and present. However, looking at the three 
glycaemic parameters in a continuous Cox regression model, the 2hPG was still the only test 
that was able significantly to predict the primary composite endpoint. Since some previous 
studies have reported on a non-linear relationship between FPG and CVD, the model was 
tested for a U- or J-shaped relationship between FPG and the primary endpoint, without any 
significant relationship being found. In addition, adding FPG as a quadratic (or even cubic) 
effect in the Cox regression model did not reveal a curvilinear association. However, such 
analysis may lack statistical power in Study I. 
5.2.2.4 Collinearity in multiple regression models 
One advantage of multivariate regression analysis is that, by including as many covariates 
as possible, the model allows us to argue that the primary predictor matters, after 
attempting to control for all the important variables that could possibly affect the 
outcome. The pitfall is the increasing risk of including variables that are correlated or act 
as an intermediate step in a casual pathway. It may be that two “independent” variables are 
so strongly correlated to one another that they are collinear. Two variables are perfectly 
collinear if there is an exact linear relationship between them, meaning mathematically a 
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correlation coefficient r equal to 1 or −1. However, studying correlations only among pairs 
of predictors is limiting. Although the r between any two X variables may be small, three 
independent variables may be highly correlated as a group. When two or more variables are 
correlated, we may have the problem of multicollinearity.159 One serious consequence of 
multicollinearity is that the standard error of the regression coefficient estimators are inflated, 
which makes some variables statistically insignificant when they should be significant. In 
Study I, the models were screened for multicollinearity which did not appear to be a concern 
as both the pairwise correlation coefficients were low between the glycaemic indicators and 
no inflation was found in the regression coefficients when building the multivariate models. 
However, multicollinearity is a matter of degree and the pattern of covariation between the 
predictor variables will determine, to some extent, which becomes significant in the final Cox 
regression model. In practice, multicollinearity is an important issue, particularly in clinical 
work, where there may be multiple standard measurements of the severity of disease.  
 
5.3 SPECIFIC FINDINGS IN PERSPECTIVE 
 
5.3.1 Prognostic implications of indicators of dysglycaemia  
The 2hPG, but not FPG or HbA1c, added prognostic information regarding future 
cardiovascular events in Study I, which is in line with the findings in several previous 
studies, as outlined below. 
 
The population-based DECODE and Collaborative analysis of Diagnostic criteria in Asia 
(DECODA) studies, comprising people of different ethnicities with and without known CVD, 
observed that the 2hPG was a better predictor of all-cause mortality and future cardiovascular 
events than FPG.136,160 The 2hPG was compared with HbA1c in two studies that were part of 
DECODE. Both tests predicted all-cause mortality, but neither FPG nor HbA1c added 
significant information if 2hPG was entered into the statistical model.161 In the observational 
Framingham Offspring Study in people with treated T2DM free from CVD, FPG, 2hPG and 
HbA1c tests were individually significant predictors of CVD during a four-year period, but 
the 2hPG was the only test that remained independently predictive of CVD when all the tests 
were modelled together.162 In the Australian Diabetes, Obesity and Lifestyle (AusDiab) study 
of 10,026 people without diagnosed T2DM and any history of CVD, the 2hPG and FPG, but 
not HbA1c, were significant predictors of all-cause mortality, while all the tests were 
significant predictors of CVD mortality.163 There was a linear relationship for 2hPG and 
HbA1c and cardiovascular risk and a J-shaped relationship for FPG. In a population-based 
cohort study from Germany, IFG and “high-risk” HbA1c were not significantly associated 
with incident cardiovascular events after adjustment for conventional cardiovascular risk 
factors. In contrast, strong associations with cardiovascular events persisted after adjustment 
among individuals with manifest T2DM, regardless of how they were diagnosed.164  
 
The Atherosclerosis Risk in Communities Study reported that people with “high-risk” HbA1c 
run an increased risk of developing T2DM and CVD independent of FPG165, but a postload 
glucose was not included in this study. The European Prospective Investigation into Cancer 
in Norfolk (EPIC-Norfolk)166 reported that HbA1c significantly predicted all-cause mortality 
and cardiovascular events, even below the threshold for the diagnosis of T2DM and 
independent of age and classic cardiovascular risk factors. However, neither a FPG nor a 
2hPG was analysed in this model. In a cohort of 8,365 individuals aged 50-74 years, adding 
IFG or high-risk HbA1c to the Systematic Coronary Risk Evaluation (SCORE) model did 
not improve cardiovascular risk prediction in individuals without T2DM during an eight-year 
follow-up.167 To summarise, it appears that the 2hPG is a stronger predictor of cardiovascular 
outcomes in population-based studies.  
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In patient populations with CAD, the Silent Diabetes Study compared the prognostic capacity 
of HbA1c with that of an OGTT in 1,015 patients without previously known T2DM 
undergoing coronary angiography. The 2hPG was closely related to the severity of CAD and 
future mortality during a three-year period and in this respect superior to FPG, whereas there 
was no association with HbA1c.168 In a retrospective study of 1,056 patients with acute 
coronary events without known T2DM, FPG and 2hPG were measured pre-discharge. The 
2hPG but not the FPG predicted future ACS during a period of 41 months. The 2hPG also 
improved the predictability of the Global Registry of Acute Coronary Events (GRACE) risk 
score.169 Unfortunately, HbA1c was not included in this study. In the present study, 2hPG 
indicating IGT (n=1,242) was significantly associated with the primary endpoint, while the 
2hPG indicating T2DM (n=435) showed a similar trend with borderline statistical 
significance, probably due to the lack of power, given the results of previous studies. 
Evidence is accumulating that it is more important to find out whether CAD patients have 
dysglycaemia, defined as either IGT or T2DM, than to classify them as having either IGT or 
T2DM.11,170 The latter is an arbitrary division that was introduced to distinguish people with 
dysglycaemia who had T2DM from those who ran a high risk of developing T2DM.171  
 
The present study adds new information by incorporating hospitalisation for heart failure in 
the primary endpoint, which traditionally only includes cardiovascular death, non-fatal MI 
and stroke. Heart failure emerges as a common and very serious complication of T2DM in 
the setting of CAD.172 The importance of heart failure is further underlined by the results of 
recent trials with the SGLT-2 inhibitors empagliflozin86, canagliflozin173 and dapagliflozin174 
in patients with T2DM and established cardiovascular disease or at high cardiovascular risk. 
SGLT-2 inhibition was associated with a reduction in cardiovascular mortality, which was 
driven by a decrease in hospitalisation for heart failure.  
5.3.2 Screening for dysglycaemia in high-risk patients 
In Study II, patients free from CVD but on treatment for hypertension and/or dyslipidaemia 
had a surprisingly high prevalence of dysglycaemia, which was relatively high even in the 
lower FINDRISC categories. Using the FINDRISC as an initial screening step to select high-
risk individuals for further blood glucose testing was therefore not helpful. The most 
reasonable explanation for this poor discriminatory ability is the high prevalence of 
dysglycaemia in the population in Study II compared with the general Finnish population in 
which the FINDRISC was developed.124   
 
The FPG was the single best test for detecting T2DM, but the use of FPG is limited as it is 
unable to detect IGT. The combination of FPG and 2hPG via an OGTT identified 92% of 
those with T2DM and the 2hPG another 20% with IGT. The superiority of this combination 
corresponds to the outcome of a previous study from EUROASPIRE IV on the glycaemic 
screening of patients with established CAD.131 “High-risk” HbA1c classified the majority 
(72%) of the present population as having glucose perturbations. It is reasonable to suppose 
that this proportion is too high. At the same time, HbA1c underestimates the prevalence of 
previously undiagnosed diabetes. Furthermore, “high-risk” HbA1c is reported to be less 
sensitive than IFG and IGT when it comes to detecting individuals with insulin resistance 
and beta cell dysfunction.175 
 
The present findings gain support from previous experience. In the Impaired Glucose 
Tolerance and Long-Term Outcomes Observational (IGLOO) study, based on 1,377 
Mediterranean participants without known CVD but with one or more cardiovascular risk 
factors,176 the prevalence of screening-detected dysglycaemia was 37% (IGT 11%; T2DM 
17%). A similar proportion, 41%, was reported by the Atherosclerosis Risk in Communities 
Study177 screening 8,286 middle-aged American participants, of whom many had 
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hypertension, dyslipidaemia and/or central obesity, with an OGTT. Further, 14% had 
screening-detected T2DM in a cross-sectional population-based study from Kuwait, in which 
more than half the participants were overweight or obese but without any history of CVD.178 
 
Since hypertension is a component of the FINDRISC, it can be argued that it is inappropriate 
to use this questionnaire in patients with hypertension. One way to investigate whether it 
matters would be to study a subgroup with only dyslipidaemia. Unfortunately, this was 
impossible, as 89% of the present study population were either being treated with blood 
pressure-lowering drugs or were found to have hypertension when investigated. Furthermore, 
statin use may increase the risk of T2DM, as well as β-blockers and possibly calcium channel 
blockers.179 However, patients on statins had a lower proportion of dysglycaemia and there 
were no significant differences for β-blockers or calcium channel blockers between patients 
with and without dysglycaemia. 
 
One alternative, limiting the need for an OGTT to 62% of the present population (those with 
IFG), would be to start screening with a FPG and continue with an OGTT only in patients 
not fulfilling the criteria for T2DM. With a strategy of this kind, 18% of patients with IGT 
would be missed. It has to be debated whether this is acceptable. It may be argued that patients 
under treatment for hypertension and/or hyperlipidaemia should have received lifestyle 
advice, the cornerstone of dysglycaemia management, so that the detection of IGT would not 
add more to their management. The present data show that primary care patients on treatment 
for hypertension and/or dyslipidaemia, in addition to undetected dysglycaemia, had a high 
prevalence of obesity, smoking and low levels of physical activity.180 These findings indicate 
that patients at risk of future cardiovascular events without established CVD require better 
risk-factor management, given the results of the Steno-2 Study94 and the reports from the 
Swedish National Diabetes Register showing that multifactorial management is imperative 
in reducing the risk of cardiovascular events.96 In the report from the Swedish National 
Diabetes Register of patients with T2DM with or without established CVD, the excess risk 
of outcomes decreased stepwise for each risk factor within target. Patients with optimal risk-
factor control had little or no age-adjusted excess risk of death, AMI or stroke.96 Furthermore, 
it was also found that levels of HbA1c, systolic blood pressure and LDL cholesterol lower 
than the recommended target levels were associated with a reduced risk of outcomes. As 
regards IGT, experiences from the Da Qing study76, the US Diabetes Prevention Program101 
and the Finnish Diabetes Prevention study181 demonstrate that an improved lifestyle can 
significantly reduce the development of overt T2DM during prolonged periods of follow-up. 
Moreover, micro- and macrovascular complications, including cardiovascular and total 
mortality, were reduced in the Da Qing study. In patients with T2DM, glucose-lowering 
drugs can be initiated if lifestyle improvements prove not to be sufficient. 
5.3.3 Implementation of screening  
Study II shows that screening for dysglycaemia in people with a high proportion of IGT or 
T2DM is far from optimal, despite the fact that the addition of dysglycaemia to other risk 
factors substantially increases the future risk of cardiovascular events including mortality.53 
 
The current guidelines recommend the opportunistic screening of individuals at risk of T2DM 
and screening is expected to be implemented in the primary health care setting. In Study III, 
it was evident that, in the specific population of Södertälje Municipality, several 
unconventional approaches were more beneficial in terms of the participation rate, the 
proportion of identified high-risk individuals and cost effectiveness. Södertälje Municipality 
was regarded as an appropriate setting for a study of different screening strategies, as its 
population consists of both immigrants and Swedish-born people, people with a different 
socio-economic status and the location of well-established workplaces in the industrial and 
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health-care sectors. The largest proportion of respondents was obtained through workplaces. 
It was, however, through co-operation with the Syrian Orthodox church that the largest 
proportion of individuals at high/very high risk, who were notably presumed to be unlikely 
to participate in a risk assessment, could be reached. The majority of these respondents were 
born outside Europe and had a lower level of education and a higher rate of unemployment. 
These factors may have contributed to differences in health awareness, understanding of the 
health-care system and limited opportunities to pay for the cost of lifestyle or medical care.182 
 
The experiences in Study III are not unique. In a Swedish community-based mass screening 
for atrial fibrillation performed in 2010-2012, participation was low in Södertälje, with many 
immigrants and a high incidence of ischaemic stroke.118 Similarly, areas with a low mean 
income and a high proportion of immigrants had lower participation rates in screening for 
aortic aneurysms compared with areas with higher socio-economic status.183 In Tower 
Hamlets, a deprived borough in the East End of London with a large minority ethnic 
population, breast cancer screening uptake was 60% in the white population compared with 
a much lower uptake among women from Pakistan (40%) and Bangladesh (37%). A multi-
channel approach through a strong partnership between community organisations, primary 
health-care centres and public health, with campaigns targeted at Pakistani and Bangladeshi 
women, increased the total screening uptake from approximately 45% to 63% in three 
years.120 Attempts have been made in Afro-American communities to introduce health 
information by approaching churches, barbershops, beauty salons and other community-
based organisations to reach people in deprived areas for the screening of cardiovascular risk 
factors and breast and cervical cancer. These settings, which are accessible to all communities 
and are frequently visited, have offered important opportunities for both the reach and the 
reinforcement of health messages.116,184–194 
 
Considering that ADDITION-Cambridge111 and ADDITION-Denmark112, did not reveal any 
reduced all-cause, CVD- or T2DM-related mortality associated with an invitation to 
screening through the primary care centres, population-based screening for T2DM is the 
subject of debate. However, ADDITION used only a single mailed invitation, with no 
reminders to non-respondents and only the primary care centres as an outreach strategy. Only 
10% of all people with newly diagnosed T2DM in the ADDITION primary care centres were 
actually identified through the screening programme. Study III strongly supports the 
assumption that screening in other settings and through different outreach strategies may be 
more effective and could have yielded a different result. Another explanation is that many 
individuals in the control group of the ADDITION studies were diagnosed through 
opportunistic screening. Studies from high-income countries indicate an increase over time 
in laboratory testing for T2DM in the absence of any formal screening programmes or 
recommendations.195 
 
Studies I and II underline that there is a significant gap between what is currently known 
about dysglycaemia prevention and screening and what is commonly practised. This 
screening inertia is difficult to understand in the light of several studies reporting that non-
pharmacological interventions in people with IGT are cost effective to reduce the risk of 
T2DM.196 A study from the US demonstrated, by using a simulation model, that a national 
community-based lifestyle programme (based on the US Diabetes Prevention Programme)73 
could delay or prevent T2DM in high-risk individuals and save USD 5.7 billion in 25 years.197 
A Swedish study of individuals with IGT using the Finnish Diabetes Prevention Study 
programme as a base also reported that lifestyle intervention would be highly cost effective 
to prevent progression of IGT to T2DM.198  
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5.3.4 Glucose measurement using the point-of-care technique  
In Study IV, glucose measurements using the HemoCue® point-of-care system corresponded 
well to the glucose levels obtained at the hospital laboratories from a practical, screening 
perspective. There were small individual differences between the HemoCue® and the hospital 
laboratory methods, as the surveillance error grid showed a high level of accuracy with 
almost all values located in the “no-risk” zone. The Bland-Altman plot indicated a tendency 
towards higher FPG measurements according to HemoCue® compared with hospital 
laboratory measurements. 
 
In a study by Stork et al., a total of 500 paired glucose values were obtained from 24 
volunteers participating in a hyperinsulinaemic glucose clamp study and analysed by both 
HemoCue® and approved laboratory standards.139 In line with the results of the present 
investigation, the agreement between the two methods was very strong. Other studies 
reported on consistently higher blood glucose, especially in the hypoglycaemic range, with 
HemoCue®, but also on lower values than with laboratory glucose.199 When several point-of-
care glucometers, including HemoCue®, were compared with standard laboratory procedures 
for the diagnosis of T2DM and IGT in 168 individuals undergoing an OGTT, the glucometers 
were less reliable than the laboratory procedures, especially in the fasting state.200 These 
results may, however, have been affected by the use of capillary blood samples with the 
glucometers, considering that glucose concentrations are reported as higher in capillary blood 
than venous blood, especially in the postprandial state.201,202 Several other factors may 
confound comparisons of glucose measurements with point-of-care and central laboratory 
methods. First, there is no universal agreement on a reference method for glucose 
determination, even though the hexokinase method is one of the most common.140–142 
Secondly, a discrepancy between two paired measurements by two devices does not 
necessarily mean that the tested method is inferior to the reference method. 
 
Since glucose is unstable in whole blood, it is important that samples are analysed without 
delay. HemoCue® analyses whole blood immediately following blood sampling, which 
prevents glycolysis, which is the most frequent and important source of pre-analytical error 
with laboratory measurement. If sample transportation to and handling at the laboratory is 
delayed, the measured plasma glucose may become lower than the actual level. In the present 
study, this possibility was at least partially overcome by inhibiting the potential of glycolysis 
by using fluoride/citrate tubes.203 In spite of this, glycolysis may have contributed, to some 
extent, to the fact that some patients had higher glucose with HemoCue® than when measured 
at the laboratory. The conversion of whole blood to plasma glucose and adjustments for 
cholesterol levels may also have affected the accuracy of HemoCue®.138  
 
The point-of-care technique has the advantage of providing an immediate analysis of the 
FPG. Furthermore, before establishing a diagnosis in the clinical setting, these patients would 
have been subjected to renewed testing of their glucose, since the diagnosis of T2DM requires 
two positive tests. To summarise, the HemoCue® point-of-care system should be regarded as 
a convenient and accurate method for glucose measurement. The acceptance of point-of-care 
glucose measurement would simplify and thereby improve patient management that is 
currently far from satisfactory, as regards dysglycaemia screening. 
 
5.4 ETHICAL CONSIDERATIONS 
Risk assessment and the screening of individuals for dysglycaemia raises several ethical 
questions. In 1968, Wilson at the Ministry of Health in the United Kingdom and Jungner at 
Sahlgrenska University Hospital in Gothenburg wrote “in theory, screening is an admirable 
method of combating disease ... [but] in practice, there are snags”.103 The concern about 
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screening emerged from the problem that disease detection may be simple, but providing 
adequate therapy to those with newly detected disease and avoiding harm to those not in need 
of treatment can be far from easy.  
 
Looking at the Wilson-Jungner criteria, T2DM satisfies many of the criteria established for 
screening programmes. It has a long asymptomatic period during which serious 
complications can develop, there are simple validated questionnaires and reliable diagnostic 
tests and interventions for glucose, blood pressure and lipids are effective.97,98 However, 
large-scale population screening programmes, such as those that have been established for 
colon and breast cancer, have not been proven to be cost effective for T2DM. If screening 
through outreach strategies other than the primary care centres were shown to be cost 
effective and the impressive effects of SGLT2 inhibitors and GLP-1 receptor analogues on 
cardiovascular outcomes in people with T2DM at high cardiovascular risk also apply to those 
at lower cardiovascular risk, screening for dysglycaemia in a broader perspective could 
perhaps be justified. The cost of large-scale screening with a simple questionnaire appears to 
be reasonably small when performed through effective channels. However, risk 
questionnaires may not always be accurate, as observed in Study II. Risk scores attempt to 
estimate the combined effects of several risk factors. They may, however, not be capable of 
analysing interaction effects in any detail, thereby making the estimates approximate. 
Furthermore, the risk of a population might also be under- or overestimated, since the 
prevalence of disease can change over time, making a once valid test inaccurate. One example 
of this is SCORE for assessing the 10-year risk of CVD based on conventional risk factors. 
The high-risk SCORE version was recommended for Central and Eastern Europe and the 
former Soviet Union. When the performance of SCORE was examined, it was observed that 
the high-risk version of SCORE underestimated the risk substantially in Russia, with an 
increase in CVD mortality, but, at the same time, it overestimated the risk in countries in 
which CVD mortality had declined.207,208 
 
Seen from a population perspective, screening for a “mass disease” provides information on 
the direction of change in important factors for public health on which interventions can be 
based. However, there is a preventive paradox according to Geoffrey Rose, “a preventive 
measure that brings large benefits to the community offers little to each participating 
individual”.209 A mass approach, like that in Study III, may reduce morbidity at population 
level but may cause anxiety and stress in individuals. In Study II, many patients were 
classified as having high-risk HbA1c without any available evidence that this was of any 
benefit to these patients in terms of treatment or prognosis. However, looking at the 
psychological aspect of screening in T2DM, its impact appears to be limited.210 For example, 
in a substudy of the ADDITION (Cambridge) trial, no clinically relevant differences were 
found for anxiety, depression, T2DM-specific worry and self-rated health between the 
screening attenders and the control participants.211 In a qualitative interview study of 23 
participants in the ADDITION (Cambridge) trial,212 T2DM screening in order to detect the 
disease at an early stage was perceived as a good thing. However, on a personal level, the 
participants tended to not pay attention to their risk. Most participants with IFG or IGT 
struggled to understand the implications of these conditions and were not intending to change 
their lifestyles. This may partly be due to lack of understanding and management protocols 
for  patients with IGT by health care providers as reported by a qualitative study of general 
practitioners in England.213 
 
In Study III, individuals who were given the opportunity to have their blood glucose 
measured at the temporary lab units did not show up, despite being informed about their 
elevated risk according to the FINDRISC. One explanation may be that these individuals did 
not take the risk of having T2DM seriously, as concluded in the ADDITION trial, or that 
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they did not assimilate the information they were given. This is clearly worrying and raises 
the question “Is risk assessment justified if individuals at risk do not undergo further 
evaluation?”. However, it may be that high-risk individuals chose to seek their primary care 
centres for further evaluation. Further information on this was not, however, available.  
 
5.5 FUTURE DIRECTIONS 
This project has shown that the three diagnostic tests for dysglycaemia differ in their 
diagnostic and prognostic capacities. These observations beg the question: do patients with  
dysglycaemia captured uniquely by the FPG, HbA1c or 2hPG tests differ in terms of 
underlying pathophysiology and future complications? Studies are needed to examine 
whether, for example, individuals diagnosed solely on the basis of HbA1c differ from those 
diagnosed only by a 2hPG when it comes to underlying mechanisms and complications. One 
hypothesis is that these two groups of patients display different levels of insulin resistance. 
This prediction could be tested by measuring markers of insulin resistance and inflammation 
in individuals diagnosed on the basis of different tests. Furthermore, intervention studies 
with, for example, SGLT2 inhibitors or GLP-1 receptor agonists of individuals diagnosed on 
the basis of FPG, 2hPG or HbA1c may shed light on the clinical relevance of these tests. 
 
In a recent study from Sweden, five clusters of patients with adult-onset diabetes, who would 
traditionally be categorised as T1DM, T2DM or LADA, were identified.214 These five 
clusters consisted of severe autoimmune diabetes, severe insulin-deficient diabetes, severe 
insulin-resistant diabetes, mild obesity-related diabetes and mild age-related diabetes. Severe 
autoimmune diabetes overlapped with T1DM and LADA but severe insulin-deficient 
diabetes and severe insulin-resistant diabetes, represented two new types of diabetes masked 
within T2DM according to the present classification of diabetes. Individuals with severe 
insulin-resistant diabetes displayed a substantially increased risk of kidney complications 
while individuals with severe insulin-deficient diabetes had the highest risk of retinopathy. 
Individuals with severe insulin-resistant diabetes and mild age-related diabetes seemed to 
have higher risk of coronary events. However, the differences in coronary events between 
the clusters were not significant when adjusted for age and sex. The findings in this PhD 
project are therefore compatible with recent evidence showing that T2DM is a heterogeneous 
disease. Our findings may help to identify T2DM subgroups with an increased risk of 
complications, bringing us one step closer to individualised medicine in which treatment is 
tailored to each patient’s individual need and risk profile. 
 
Study I did not have the power to look into single cardiovascular outcomes rather than a 
composite endpoint. The prognostic value of the screening tests may differ with regard to 
different cardiovascular outcomes, which would be interesting to investigate in more detail 
in future, larger samples. Moreover, the need to find simple screening strategies remains an 
important goal. It would be valuable to validate the time-saving algorithm based on the use 
of one hour postload glucose from an OGTT in patients at high risk of future cardiovascular 
events that was suggested based on EUROASPIRE IV patient data.215  
 
The populations in Studies I and II at risk of future cardiovascular events need better risk 
factor control. Today, there is a substantial gap between guideline recommendations and 
daily practice. In future studies, we need to examine how optimally to implement existing 
knowledge on the prevention of dysglycaemia and CVD in clinical practice. The findings of 
Study III indicate that unconventional outreach strategies may be effective, e.g. through 
churches, employers and social media, in place of the conventional primary care setting. 
However, it remains to be shown whether these unconventional outreach strategies will also 
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be effective in providing lifestyle interventions in individuals at elevated risk of 
dysglycaemia.  
 
Many individuals with an elevated risk of dysglycaemia are believed not to have undergone 
further investigation in Study III, even though they were offered medical assistance. It is not 
only an interesting but also a very important topic for future studies to explain why these 
individuals were not interested in following up their questionnaire results. At the same time, 
novel strategies for motivating high-risk individuals to attend screening should be examined.  
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6 CONCLUSIONS 
1) When comparing the prognostic capacity of FPG, HbA1c and 2hPG regarding future 
cardiovascular events in patients with CAD, the 2hPG was the only test that provided 
independent prognostic information. An OGTT should therefore be performed in patients 
with a high risk of future cardiovascular events.  
 
2) The prevalence of previously undetected dysglycaemia was high in patients treated for 
hypertension and/or dyslipidaemia but without established CVD. The use of the FINDRISC 
questionnaire did not reduce the demand for blood testing. Screening in this population 
should be initiated with at least a FPG.  
 
3) The choice of outreach strategy was important to reach high/very high risk groups for 
T2DM and for screening costs in the immigrant-dense, thereby heterogeneous, population of 
the Municipality of Södertälje. Future screening programmes should carefully consider 
their choice of outreach strategies in relation to the characteristics of the screened 
population. 
 
4) The HemoCue® point-of-care system is accurate for dysglycaemia screening and its use 
saves time when performing an OGTT.  
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